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Abstract
Background: Cancer cells have a complex microenvironment that helps create optimal
conditions for cancer proliferation. Nutrients such as glucose will pass through a tortuous and
leaky vascular structure developed by cancer cells, and are subsequently distributed and
transported inside the cancer cells to meet their metabolic demands. This leaky and poorly
organized vasculature leads to a buildup in the interstitial fluid pressure surrounding the tumor,
subsequently resulting in tumor hypoxia. Due to an overreliance on glycolysis, more acid and
protons are produced by cancer cells, leading to a more acidic environment which, in
combination with tumor hypoxia, often leads to a poor patient outcome. This thesis aims to
explore the intrinsic relationship between tumor perfusion, glycolysis and its pH environment
using a C6 rat model of glioma.
Methods: All rats were implanted with 1 million C6 glioma cells using stereotactic surgery.
The growth of tumor cells was monitored either with computed tomography perfusion (CTP)
or magnetic resonance imaging (MRI). Once tumors had reached the optimal size, tumor
perfusion was measured using CTP. Tumor glycolytic metabolism was measured using
positron emission tomography (PET) with 18F-flurodeoxyglucose (FDG) and MR spectroscopy
imaging (MRSI) using hyperpolarized [1-13C]pyruvate. Chemical exchange saturation (CEST)
MRI was also used to investigate tumor glucose distribution (glucose contrast enhancement,
or ∆CEST) and pH environments (intra-/extracellular pH, pHi and pHe respectively and
simultaneously) during/after a glucose infusion/injection. All experimental procedures were
completed within 24 hours. Measurements of tumor perfusion, glycolysis, ∆CEST and pH
environments were correlated using Pearson’s correlation.
Results: Tumor perfusion measurement of permeability surface-area product (PS) was
significantly correlated with tumor glycolysis measurement of lactate to pyruvate ratio
(Lac:Pyr) from hyperpolarized MRSI as well as ∆CEST. Tumor Lac:Pyr was also significantly
correlated with tumor pHi. Tumor metabolic rate of glucose derived from dynamic PET was
significantly correlated with tumor pHi and pHe.
Conclusion: This research showed the possibility of measuring the intracellular and
extracellular pH environment simultaneously. Multimodal imaging approaches provided a
more complete picture of the tumor microenvironment and helped elucidate the intrinsic
relationship between tumor perfusion, glycolysis and the pH environment.

Keywords
multimodal imaging, glioblastoma multiforme, cancer perfusion, cancer metabolism, cancer
pH, computed tomography (CT), magnetic resonance imaging (MRI), chemical exchange
saturation transfer (CEST), pH imaging, amine and amide concentration independent
detection (AACID), AcidoCEST, hyperpolarized [1-13C]-Pyruvate MRSI, 18Fflurodeoxyglucose positron emission tomography (PET), PET kinetic analysis.
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Summary for Lay Audience
Cancer cells have a complex microenvironment that helps create optimal conditions for them
to survive and grow. Nutrients that are essential for cancer growth such as glucose will be
delivered to the cancer cells using a poorly developed vessel system that is also developed by
cancer cells. The amount of nutrients delivered is based on the energy needs of cancer cells.
These delivered nutrients will then be used for energy production to support the cancer cells’
survival. Glycolysis is an energy production method that is mainly used by cancer cells. During
glycolysis, glucose acts as a fuel and helps to produce enough energy to meet the energy
demands of cancer cells. However, this energy production process is very inefficient, leading
to the production of acids as a side product. As a result, this makes the environment where
cancer cells reside very acidic. This acidic environment will further help cancer cells to avoid
detection by the host’s immune system, killing off the healthy cells around the tumor, and help
cancer cells to spread into the surrounding areas. Moreover, the acidic cancer environment will
lead to the formation of more vessels and further help the delivery of nutrients to cancer cells.
This completes the vicious cycle between the delivery of cancer nutrients, the energy needs of
cancer cells, and the acidic environment around cancer cells.
It is important to explore the relationships between the delivery process of nutrients to cancer
cells to meet their metabolic demand, cancer cells’ energy production and the production of
acid due to the inefficient energy production commonly found in cancer. Measuring these
changes with non-invasive imaging methods, we will get more insight into cancer cell growth
and spreading. Ultimately, we can use this information to achieve a better treatment outcome
by stopping this vicious loop.
This thesis aims to explore these intrinsic relationships among cancer nutrients delivery, energy
need and the acidic environment; and better understanding the environment that the cancer
cells reside using a number of complementary medical imaging methods in a clinically
translatable animal cancer model.
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Chapter 1

1 Introduction
This thesis explores the intrinsic relationship between cancer perfusion and cancer
metabolism as well as the effect of tumor metabolism on tumor pH environments. We first
evaluated whether glucose chemical exchange saturation transfer (glucoCEST) magnetic
resonance imaging (MRI) is a perfusion or glycolysis measurement. In Chapter 2, we
compared glucoCEST to perfusion measurements from computed tomography perfusion
(CTP), and glycolysis measurements of standardized uptake value (SUV) from
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flurodeoxyglucose (FDG) positron emission tomography (PET) imaging and lactate-topyruvate ratio (Lac:Pyr) from hyperpolarized [1-13C]pyruvate MR spectroscopy imaging
(MRSI). In Chapter 3, we compared the tumor intracellular pH (pH i) environment
measured using amine and amide concentration independent detection (AACID) to tumor
glycolysis measurement of SUV and Lac:Pyr. Finally, in Chapter 4, we compared both the
tumor pHi and extracellular pH (pHe) environments to tumor glycolysis measurements
obtained from dynamic FDG-PET. The purpose of this chapter is to provide an introduction
and motivation for the presented research. Section 1.1 outlines the motivation and general
organization of the thesis. A brief survey of glioblastoma multiforme, tumor metabolism
and its pH environment is presented in Sections 1.2 and 1.3. An introduction to CEST
theory and application to pH measurement is presented in Section 1.4 followed by
discussion of PET imaging and PET analysis in Section 1.5. A brief discussion of CTP
theory is in Section 1.6 and hyperpolarized [1-13C]pyruvate MRSI is in Section 1.7.

1.1 Motivation and overview
Cancer cells have a complex microenvironment that helps to create optimal conditions for
cancer proliferation. Nutrients such as glucose pass through a tortuous and leaky vascular
structure developed by cancer cells, are distributed, and then transported inside the cancer
cells to meet their metabolic demands. This leaky vasculature leads to a buildup in the
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interstitial fluid pressure surrounding the tumor, which, along with the poorly organized
vasculature, results in tumor hypoxia [1,2]. In the 1920s, Dr. Warburg and his colleagues
discovered that cancer cells rely on glycolysis as their main source of energy production
[3,4]. Cancer cells will upregulate glucose transporters and rely on glycolysis for energy
production even with sufficient oxygen supply (known as aerobic glycolysis) [3,5].
Anaerobic glycolysis taking place in the cell cytosol is a less efficient means of energy
production in contrast with oxidative phosphorylation (or PCA cycles) which takes place
in the mitochondria. This is evident by comparing the number of adenosine triphosphate
(ATP) produced at the end of each process, with 2 ATP produced from glycolysis and 38
ATP from the Krebs cycle. In fact, the majority of glucose will be converted into lactic
acid via anaerobic glycolysis [4,6]. The reason behind this selective energy production
method is still highly debated but it is widely believed that this is the result of evolution
for cancer cell proliferation as the side products (proteins and enzymes) produced through
glycolysis will aid in cancer cell proliferation [3]. As a consequence of the upregulation of
glucose transporters and overreliance on glycolysis, elevated protons and acids are
produced (as shown in Figure 1.1), resulting in a more acidic microenvironment for cancer
cells. However, a lower pH environment would normally lead to intracellular acidosis
which could eventually result in cell death or apoptosis. To avoid cell death, cancer cells,
in turn, upregulate transporters (such as monocarboxylate-H+ efflux transporters)
responsible for transporting acid and protons from the intracellular space to the
extracellular space, and eventually achieve a pH gradient across the cell membrane i.e. a
slightly more basic pHi environment in combination with a more acidic pHe environment
and contributes to immune-resistance [7–9]. The acidic pHe further contributes to tumor
invasion to surrounding cells by damaging the extracellular matrix [4,7,8]. The relationship
between cancer perfusion, metabolism and its pH environment are intricate and often
closely interlinked. By evaluating their relationship, we can provide insight into tumor
proliferation and potentially achieve a better treatment outcome. This thesis therefore aims
to explore these intrinsic relationships and better understand the tumor microenvironment
in vivo using a multimodal imaging approach.
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1.2 Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most malignant type of brain tumor. It has an
incidence of 4 per 100,000 people in Canada, and accounts for 12-15% of all intracranial
tumors and 50-60% of astrocytic tumors [10]. Despite the advances in treatment modalities,
including aggressive treatment methods combining surgery, chemotherapy, and
radiotherapy, it remains largely incurable and has a low survival rate [10].

Figure 1.1: An illustrative figure of tumor metabolism. The majority of glucose transported
into the cell will go through glycolysis and is converted into lactic acid. Lactic acid will be
pumped out into the extracellular space leading to a more acidic pHe versus a neutral or
slightly basic pHi.
Glioma cells are cancer cells derived from glial cells, a type of non-neuronal cell that
supports and protects neurons while also maintaining homeostasis in the central nervous
system (CNS). The exact origin of glioma cells still remains uncertain, as neural stem cells,
astrocytes and oligodendrocytes are all considered as possible precursors of glioma cells
[11]. Astrocytoma is the most common type of glioma [12], and anaplastic astrocytoma,
with a high degree of anaplasia, can infiltrate normal brain tissue diffusively and tends to
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progress into GBM [13]. GBM is the most aggressive form of astrocytoma, and is made up
of differentiated neoplastic astrocytes [14]. Elevated mitotic activity, angiogenesis and
necrosis are regarded as hallmarks for GBM [14,15]. These are reflected by the complex
metabolic and perfusion properties of GBM.
C6 cell lines were first developed in adult Wistar rat composing pleomorphic cells with
distinctly shaped nuclei [16]. C6 glioma cells are spindle-like cells that possesses high
similarity with human GBM, C6 rat model of glioma has also shown to be more superior
than other rodent glioma models in terms of morphological characteristics [17,18]. C6
glioma cell implantation models have been developed using Wistar rats and the histological
results have reflected similar features as human GBM i.e. with large necrosis and high
mitotic index [19]. As a result, we used a C6 Wistar rat model of glioma in this thesis.
However, C6 glioma cells might induce immune response mimicking certain anti-tumor
response [20], therefore, the efficacy of immunotherapy should be carefully interpreted
when using C6 glioma cells.

1.3 Cancer cell metabolism and its pH environment
Glucose is the most important source for cellular energy production. In normal mammalian
cells, glucose is used for an efficient energy production called the Krebs cycle and
subsequent electron transport chain reactions under sufficient oxygen supply that takes
place in the mitochondria inside of the cells. Equation 1.1 indicates the reaction which
connects glycolysis and the Krebs cycle. Equation 1.2 indicates the overall energy
production via the Krebs cycle [21].
Pyruvate + CoA + NAD+ →
acetylCoA + NADH + CO2 [Equation 1.1]
6O2 + Glucose + 36ADP + 39Pi + 10NADH + 2FADH2 → 36ATP + 6CO2 +
6H2 O + 10NAD+ + 2FAD

[Equation 1.2]

where NAD+ is nicotinamide adenine dinucleotide, CoA is coenzyme A, Acetyl-CoA is
acetyl coenzyme A, NADH is the reduced form of NAD+, ADP is adenosine diphosphate
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and ATP is adenosine triphosphate, FADH2 is flavin adenine dinucleotide, FAD is flavin
mononucleotide.
However, cancer cells mainly rely on the process of glycolysis (known as the Warburg
effect) regardless of the surrounding oxygen environment, as shown in Equation 1.3 and
Figure 1, for energy production:
Glucose + 2NAD+ + 2ADP + 2Pi →
2Pyruvate + 2NADH + 2H + + 2ATP + 2H2 O [Equation 1.3]
where ADP is adenosine diphosphate and Pi is inorganic phosphate.
Although glycolysis is a less efficient energy producing pathway compared to the Krebs
cycle (producing only 2 ATP vs. 36 ATP produced in the Krebs cycle), cancer cells rely
on glycolysis to create an optimal environment for them to proliferate, avoid detection from
immune cells and avoid apoptosis [4,22]. As a result of this dependency on glycolysis,
more H+ protons and lactic acids are produced as by-products. They are transferred out of
the cells to the extracellular space via proton and acid transporters such as monocarboxylate
transporters (MCTs) to avoid apoptosis induced by intracellular acidosis [23]. As a result,
a neutral pH or slightly alkaline pH environment is established in the intracellular space ≥
7.1 [4,6,24,25], along with a slightly acidic extracellular pH environment ranging from 6.7
to 7.1 [4,22,25,26].
pH homeostasis is essential for the survival of human biological systems, with several
systems involved simultaneously to ensure the proper pH balance is maintained. In
metabolically active cells, the lactate and H+ are side products from aerobic glycolysis and
Krebs cycles and will accumulate in the intracellular space. The lactate and H+ would lead
to acidosis which will lead to apoptosis in the intracellular space of cells if left alone. As a
result, transporters such as MCTs are activated after a more acidic intracellular
environment is detected and facilitate transportation of the acid to the extracellular space.
The acid will then be transported to the blood stream and neutralized by the liver and
kidney. As a result, the system will maintain pH homeostasis to avoid cell damage in both
the intra- and extracellular space. However, in the case of cancer cells, due to the overreliance on glycolytic metabolism (Warburg effect), an excess amount of acid and H+ are
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produced by glycolysis in the cytosol. In combination with the poor perfusion environment
from a tortuous vasculature established by cancer cells and the elevated number of proton
transporters, a greater reduction in local pH will be induced.
Ionization or dissociation of water molecules to H+ and OH- occurs naturally:
H2 O ↔ H + + OH − [Equation 1.4]
This self-ionization process of water is reversible, and at equilibrium the activity of the
dissociation process is defined as the product of the molar concentrations of the ions,
symbolized by the ionization constant kw.
k w ↔ [H + ][OH − ] [Equation 1.5]
Where [H+] and [OH-] are the molar concentrations of the ions.
Danish chemist Søren Peter Lauritz Sørensen introduced the concept of pH to measure the
acidity or alkalinity in an aqueous solution [27]. pH is a logarithmic measurement, and it
inversely indicates the concentration of H+ in an aqueous solution as shown in Equation
1.6.
pH = −log10 [H + ] [Equation 1.6]
In the pH scale at 25 °C, a solution with pH less than 7 is regarded as acidic, pH of 7 is
defined as neutral, and a pH greater than 7 is considered as basic. If intra- and extracellular
[H+] can be measured in the biological tissue, the pHi and pHe can in turn be calculated
using Equation 1.6.
Traditionally, pH values have been measured using microelectrodes based on a difference
in potentials between the two electrodes [28]. pH can also be measured via positron
emission tomography (PET), magnetic resonance spectroscopy imaging (MRSI) and
immunohistochemistry [8,9,29]. However, these methods are either invasive or possess
limited spatial resolution. Novel MRI imaging techniques provide the possibility of
measuring the in vivo pH environments non-invasively and with high-resolution.
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1.4 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a diagnostic imaging tool that is widely used in the
clinical setting. It is able to image the magnetic dipole moment of hydrogen (H+) as it
interacts with the environment under a magnetic field. In an external magnetic field (B0)
the magnetic dipole moment will precess around the direction of B0 at the Larmor
frequency:
ω0 = γB0 [Equation 1.7]
where γ is the gyromagnetic ratio associated with magnetic dipole moment of the
corresponding proton.
Chemical shift is the resonant frequency of a nucleus relative to a standard in a magnetic
field, and it is normally expressed in δ or ∆ω with the unit of parts per million (ppm).
ppm =

Hz
MHz

[Equation 1.8]

For CEST MRI, the water resonance frequency is used as a reference and assigned a value
of 0 ppm [30,31], whereas in proton MRS the water resonant frequency is normally
assigned at 4.75 ppm, and the reference at 0 ppm is tetramethylsilane [32–34].

1.4.1 Chemical exchange saturation transfer (CEST)
Chemical exchange saturation transfer (CEST) was first developed by Balaban and
colleagues in 2000 [35]. It is based on the proton exchange between metabolites with low
proton concentration (on the order of μM to mM) and the neighboring water pool which
possesses a much larger proton concentration (~110 M) as shown in Figure 1.2. This
exchange behavior occurs naturally, and the exchange rate from the metabolite to water is
denoted as kXB, where pool B is the water pool and pool x is the pool associated with the
metabolite. Inversely, the proton exchange rate from the water pool to the metabolite is
denoted as kBX. Due to the significant difference in proton concentration between the
metabolite pool and the water pool, the equilibrium exchange rate kex = kXB + kBX ≈ kXB.
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To effectively detect signals using CEST, the metabolites of interest should have a slow to
intermediate exchange regime with the equilibrium exchange rate (kex) ≤ ∆ω [30,31,36].
When a radiofrequency (RF) pulse is applied at the resonant frequency of the exchanging
proton on the metabolite, saturation of the associated proton on the metabolite will be
achieved and can be detected on the proton spectrum. The saturated proton from the
metabolite can exchange with an unsaturated proton from the neighboring water pool,
resulting in the saturation being transferred to the water pool. After applying the RF pulse
for a certain amount of time (tsat) the exchange will reach saturation (Ssat). This enables the
indirect detection of endogenous or exogenous metabolites by measuring the signal
saturation from proton exchange observed as a decrease in water signal after the exchange

Figure 1.2: A pictorial representation of proton exchange between a metabolite and its
neighboring water, this exchange behavior occurs naturally. After the saturation of the
metabolite proton is achieved by on-resonance radiofrequency irradiation, the saturated
proton can be exchanged with a water proton and in turn transfer the saturation to the water
pool. The exchange rate from metabolite to the water pool is denoted as kXB and the reverse
exchange rate is denoted as kBX. The protons in red denote the saturated protons, and the
protons in black denote the unsaturated protons.
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reaches saturation. The CEST or Z-spectrum is widely used to quantify metabolite CEST
signals, it is plotted as the normalized magnetization of water (Ssat/S0, S0 denotes the
unsaturated signal) as a function of saturation offset (∆ω). The magnetization transfer ratio
asymmetry (MTRasym) is used to minimize direct saturation on water proton as its effect is
symmetrical with respect to the water saturation frequency (assigned as 0 ppm) as shown
in Equation 1.9. It is important to note that the effect of magnetization transfer (MT) might
not be symmetrical around the water peak for some CEST agents such as diamagnetic
CEST (DIACEST) agents [37]. In addition, the nuclear overhauser effect (NOE) is also not
symmetrical around the water peak [38], which can also contaminate the measurement of
MTRasym. However, it is still useful when comparing the difference between pre- and postcontrast assuming the effects on MT and NOE are constant [39]. The area under the curve
(AUC) for the MTRasym spectrum is associated with the concentration of the metabolite of
interest within the range of its resonant frequencies. An illustrative example of a Zspectrum and its corresponding MTRasym spectrum can be found in Figure 1.3.
MTR asym =

S−∆ω − S∆ω
S0

[Equation 1.9]

Where S-∆ω and S∆ω are the proton signals at -∆ω and ∆ω respectively.
The Bloch-McConnell equation is commonly used to describe the proton exchange effect
[40] as shown by Equation 1.10:
d𝐌
dt

= A𝐌 + 𝐂 [Equation 1.10]

with an analytical solution [40]:
𝐌 = (𝐌𝟎 + A−1 𝐂)eAt − A−1 𝐂 [Equation 1.11]
where M is magnetization vector with dimensions that best describe the case-specific
proton-exchange models, M0 is the thermal equilibrium magnetization vector, A is a block
matrix of associated coefficients for the solution and C is a constant vector for the solution.

1.4.1.1 GlucoCEST
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Figure 1.3: An illustrative figure of the Z-spectrum in blue and its associated MTRasym
spectrum in red for a biological system containing glucose. The shaded orange area
represents the AUC for MTRasym spectrum, and it is related to the concentration of glucose
molecules.
CEST MRI can indirectly detect metabolites at low concentration via the proton exchange
regime between the metabolites and water as mentioned above. D-glucose, the naturally
occurring form of glucose molecules [41], is used as a primary energy source in most
cancer types [3] and can be detected using CEST MRI in vivo.
In solution, D-glucose possesses two anomeric forms, α (36%) and β (64%) [41] as shown
in Figure 1.4.
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Figure 1.4: Two anomeric forms of D-glucose. Four resonant frequencies at 0.66, 1.28,
2.08 and 2.88 ppm are associated with these two forms of D-glucose.
Both configurations have a chemical shift from water of 0.66 ppm for the proton on the OH on the 6th carbon atom; chemical shifts of 1.28 ppm for the protons on the 3 -OH groups
at the position of 2, 3 and 4; and chemical shifts of 2.08 (α) or 2.88 (β) ppm for the proton
on the hydroxyl group at position 1 depending on the anomeric forms. Chemical shift is
independent of pH and temperature, therefore, 4 chemical shifts at 0.66, 1.28, 2.08 and
2.88 ppm can be detected from D-glucose molecules using CEST MRI as shown in Figure
1.3.
Two strategies have been developed to utilize D-glucose as a contrast agent for CEST MRI,
either by measuring endogenous glucose or using D-glucose as a contrast agent to achieve
glucose contrast enhancement (GCE) [42–44]. The in vivo glucoCEST signals are mainly
derived from the endogenous glucose molecules present in the interstitial or extracellular
space [43,45]. A Z-spectrum that consists of all resonant frequencies associated with the
glucose molecule will be acquired. The corresponding MTRasym will be derived, and the
AUC will be calculated to represent the concentration of glucose. This has been used to
monitor the immunotherapy treatment response targeting tumor glycolytic metabolism
such as treatment with a mammalian target of Rapamycin inhibitor (rapamycin) [46]. GCE
CEST requires an injection or infusion of D-glucose solution, and it has been used to
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investigate tumor perfusion such as tumor blood flow and vascular permeability
[42,45,47,48]. GCE is quantified by comparing the difference between post/duringinfusion and pre-infusion MTRasym spectra. Some groups have also proposed that it could
be used to measure tumor metabolism [43,49].

1.4.1.2 CEST with pH
CEST MRI is based on the process of proton exchange. kex is pH sensitive and the effect
of pH on kex can be generalized by Equation 1.12a and 1.12b:
k ex = k a [H + ] + k b [OH − ] + k 0 [Equation 1.12a]
= k1 ∙ 10pH−7 + k 0 [Equation 1.12b]
where k0 is rate constant for spontaneous proton exchange between water and the
exchangeable proton on the metabolite, ka is the rate constant for the acid-catalyzed proton
exchange and kb is the rate constant of the base-catalyzed proton exchange between water
and metabolites with exchangeable protons and can be generalized by Equation 1.12b for
base-catalyzed exchanges. kex will affect the magnitude of CEST as shown by the
generalized analytical solution for the Bloch-McConnell equation [36,40,50]:
Z(∆ω, t ) = (Pzeff Pz Zi − Z ss (∆ω))e−R1ρ (∆ω)t + Z ss (∆ω) [Equation 1.13]
Z ss (∆ω) = Pz R

R1
1ρ (∆ω)

[Equation 1.14]

where Pz is the projection factor on the z-axis of the rotating frame; Peff is the projection
factor on the z-axis of the effective frame, Pz = Peff ≈ cosθ, θ is the flip angle of the
preparation pulse before and after continuous wave irradiation; Zi is the initial Zmagnetization (Zi = Mi/M0); Zss is the steady-state Z-spectrum signal; and R1ρ is the
longitudinal relaxation rate in the rotating frame (R1ρ = 1/T1ρ).
R1ρ (∆ω) = R eff + fb k ex ω2+k
1

ω21
ex

(k−1
ex +R2b )

[Equation 1.15]

Reff is water proton relaxation rate in the rotating frame, fb is the relative population fraction
(fb = M0,b /M0,a). [36,40,50].
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In general, CEST can estimate the pH environment in which the proton exchange process
takes place either by performing a phantom experiment to relate the CEST signal with the
corresponding pH [31,51,52], or by isolating kex using an Omega plot derived from an
experiment with varying B1 [53]. However, proton exchange detected using CEST is a
delicate process and can be affected by other factors such as temperature, solute proton
concentration, amplitude of B1 and the relaxation time constants for the bulk water (T1 and
T2) [30,31].

1.4.1.3 Amine and amide concentration independent detection
(AACID)
Amine and amide concentration independent detection (AACID) was developed by
exploiting the change in the exchange rate of amine and amide protons due to change in
pHi [51,54,55]. Endogenous amide and amine metabolites can be found in the intracellular
space, and the proton exchange can be captured using CEST. Their signals can be seen on
the Z-spectra or MTRasym spectra at 3.5 and 2.75 ppm in an illustrative example as shown
in Figure 1.5a and b. The kex for protons of amine and amide can be described using
Equation 1.16 and Equation 1.17 [51]:
k amine = 10pH−4.2 [Equation 1.16]
k amide = 5.75 × 10pH−6.4 [Equation 1.17]
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A general analytical solution can be used to satisfy the Bloch-McConnel equation as
mentioned above, and a 3-pool exchange model with the individual amine, amide and water

Figure 1.5: Illustrative simulation results of a 3-pool model on the top row (a-c) and a 7pool model in the bottom row (d-f). The resultant Z-spectra (a) along with their
corresponding MTRasym spectra (b) and the AACID values at their associated pHs (c) in a
biological system without the presence of glucose. When glucose is added to the system,
the simulation results for the Z-spectra (d), corresponding MTRasym spectra (e) and the
AACID values at their associated pHs (f) are shown above. The dotted lines in panel c) and
f) denote the line of best fit.
pools (as shown in Figure 1.5a) can be set up to simulate the CEST signals at various pHs.
After calculating AACID using Equation 1.18, pH is plotted against its corresponding
AACID values as shown in Figure 1.5c, a linear relationship can be found within tumor
biological pH range [9,56]. A 7-pool exchange model is used to simulate a biological
system containing glucose, as mentioned above 4 pools are associated with the 4 proton
exchange sites on glucose, and the remaining 3 pools are amine, amide and water pools
respectively. The Z-spectra and their corresponding MTRasym spectra at their associated
pHs are plotted in Figure 1.5d and Figure 1.5e, and the AACID with the presence of
glucose is plotted against pH as shown in Figure 1.5f. The linear relationship between
AACID and pH still stands even with glucose present when comparing Figure 1.5c and
Figure 1.5f.
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𝐌𝐳(𝟑.𝟓𝟎 𝐩𝐩𝐦) × (𝐌𝐳(𝟔 𝐩𝐩𝐦) − 𝐌𝐳(𝟐.𝟕𝟓 𝐩𝐩𝐦) )

AACID = 𝐌𝐳

(𝟐.𝟕𝟓 𝐩𝐩𝐦) × (𝐌𝐳(𝟔 𝐩𝐩𝐦)

− 𝐌𝐳(𝟑.𝟓𝟎 𝐩𝐩𝐦) )

[Equation 1.18]

1.4.1.4 AcidoCEST
Similar to AACID, acidoCEST also takes advantages of the different proton exchange
behavior under different pH environments for certain metabolites. Distinct from AACID,
an exogenous contrast agent, iopamidol, is introduced [57]. Iopamidol, cannot go into the
intracellular space, therefore, it is used to evaluate pHe. The proton exchange of the protons
on two amide groups (as shown in Figure 1.6) can be detected using CEST, and can be
modeled using the following equations [57]:
k amide = 1.2 × 10pH−4.1 [Equation 1.19]
k amide = 1.2 × 10pH−4.6 [Equation 1.20]

Their CEST signals can be seen on the Z-spectra at 4.3 and 5.6 ppm as shown in Figure
1.7a. A similar 3-pool exchange model with pools associated with the 2 proton exchange
sites on the amide functional groups on iopamidol and neighboring water molecules can be
defined using the same Bloch-McConnel analytical solution described above. Meanwhile,
a 7-pool exchange model can be used to simulate CEST signals with the presence of

Figure 1.6: The chemical structure of Iopamidol, the two amide functional groups provide
proton exchange sites (in red) with neighboring water.
glucose molecules similar to what has been described in Section 1.4.1.3. The Z and
MTRasym spectra are plotted under different pH conditions as shown in Figure 1.7. The
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acidoCEST method utilizes a ratiometric measurement (RST) between the CEST singles of
the two amides either using Equation 1.21 derived in the original publication [57]:
[(M −M )/M ](4.2 ppm)

R ST = log10 [(M0 −M𝑠 )/M0](5.5 ppm) [Equation 1.21]
0

𝑠

0

which indicates a linear relationship between pH and RST; or using the simplified version
of the equation with Equation 1.22 as described by Longo et al [58] with good accuracy
but an non-linear relationship between pH and RST.
R ST =

MTRasym (4.2 ppm)
MTRasym (5.5 ppm)

[Equation 1.22]

Both methods indicate a directly proportional relationship between acidoCEST and the
corresponding pH within the tumor biological pHe range [57,58]. The simplified method
indicated by Equation 1.22 is used to obtain a relationship between pH and acidoCEST
measurements without and with the presence of glucose as shown in Figure 1.7c and 1.7f.
The relationship is not affected by the presence of glucose by comparing these two panels
from Figure 1.7.

1.4.1.5 Simultaneously measuring pHi and pHe
The same analytical solution to Bloch-McConnell equation adapted from Zaiss et al
[36,40,50,59] is used to simulate the possibility of measuring pHi and pHe simultaneously
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Figure 1.7: Illustrative simulation results of a 3-pool model on the top row (a-c) and a 7pool model in the bottom row (d-f). The resultant Z-spectra (a) along with their
corresponding MTRasym spectra (b) and the RST at their associated pHs (c) in a biological
system without the presence of glucose. When glucose is added to the system, the
simulation results for the Z-spectra (d), corresponding MTRasym spectra (e) and the RST at
their associated pHs (f) are shown above. The dotted lines in panel c) and f) denote the line
of best fit.
with the presence of glucose at different concentrations and with various pH environments
in a biological system with the presence of endogenous amine, amide, and exogenous
iopamidol using AACID and acidoCEST respectively.
A 9-pool model is used, pool A is the water pool, pool B, C, D, E are associated with the 4
proton exchanging sites on the glucose molecule, pool F is associated with endogenous
amine, pool G is the endogenous amide pool, pool H and I are the proton exchange sites
arising from the two amide functional groups on the iopamidol molecule as mentioned
above.
As shown by the results of the simulation (in Figure 1.8), the presence of glucose solution
does not possess a simple main effect on pHi and pHe measured using AACID (Figure
1.8c) and acidoCEST (Figure 1.8d) respectively, meanwhile, AACID and acidoCEST do
not interfere with each other when measuring pHi and pHe when comparing to the results
shown in Figure 1.5f and Figure 1.7f.
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Figure 1.8: An illustrative simulation result of a 9-pool exchange model: the Z-spectra and
their corresponding MTRasym spectra at different pHs are shown in a) and b) respectively.
pH vs. AACID and RST are plotted in c) and d) respectively.

1.4.2 Hyperpolarized [1-13C]pyruvate MRSI
Cellular anaerobic glycolysis can also be measured using magnetic resonance spectroscopy
(MRS) using hyperpolarized [1-13C]pyruvate. In cancer, especially under hypoxic and
lower pHe environment, the majority of the glucose will go through anaerobic glycolysis.
As a result, pyruvate is produced via glycolysis as shown in Equation 1.3, however most
of the produced pyruvate is converted to lactate acids by lactate dehydrogenase as shown

19

in Figure 1.1, instead of being utilized for the Krebs cycle for more efficient energy
production [3–6]. Hyperpolarized [1-13C]pyruvate MRSI takes advantage of this metabolic
behavior. After injection, [1-13C]pyruvate is transported inside the cells using the
monocarboxylate transporter (MCT) and then converted into [1-13C]lactate [60].
The first carbon on pyruvate can be labelled with 13C and hyperpolarized using a process
to enhance the magnetization of the first carbon by increasing the degree of alignment with
the magnetic field of the carbon nucleus [34,61]. The hyperpolarization of the carbon
nucleus can be achieved using a method called dynamic nuclear polarization [32,33],
through which the spin polarization from the electron is transferred to the nucleus mediated
by microwave irradiation. In order to utilize the hyperpolarized [1-13C]pyruvate for in vivo
use, a dissolution process needs to be performed, during which the hyperpolarized [113

C]pyruvate is mixed with superheated buffer solution at high pressure. As a result of

hyperpolarization using dynamic nuclear polarization, a 10,000-fold increase in the MRI
signal from hyperpolarized [1-13C]pyruvate is achieved compared to thermal equilibrium
[33,34].
MRSI is used to detect the signals from[1-13C]pyruvate as well as [1-13C]lactate to measure
the cancer aerobic glycolytic metabolism. The ratio of lactate and pyruvate (Lac:Pyr) can
be obtained by dividing the amplitude of the lactate peak over the amplitude of the pyruvate
peak on the spectrum, and the regional map of Lac:Pyr as an evaluation of anaerobic
glycolysis can be constructed.

1.5 Computed tomography perfusion
The perfusion properties of different tissues can be studied using perfusion imaging
techniques by monitoring the passage of a contrast agent as it travels through these tissues
[62]. A change of image intensity can be captured with perfusion imaging as the contrast
agent passes through the vasculature. Computed tomography perfusion (CTP) is a wellestablished perfusion-imaging technique, using an iodinated contrasted agent to
characterize the tissue perfusion properties. CT imaging is based on the x-ray attenuation
through different tissues with signal intensity depending on the electron densities of
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different tissue types (i.e., soft tissue or bone). The injected iodinated contrast agent
produces distinct signal intensity as it traverses through the tissue.
To quantitatively evaluate the different tissue perfusion properties, the tracer kinetics of
the contrast agent can be defined using a Johnson-and-Wilson model [63,64]. A tissue timeconcentration curve Ct(t) can be defined using the tissue image signal intensity as a function
of time to represent the change in tissue contrast concentration over time. Similarly, an
arterial input function Ca(t) is defined as the change in image intensity at an input artery to
the tissue (i.e., carotid artery as an input artery to study brain perfusion) as a function of
time. Tissue perfusion characteristics such as blood flow (BF), blood volume (BV) and
permeability-surface area product (PS) can be estimated from tracer kinetic analysis:
Ct (t) = Ca (t) ⊗ BF ∙ R(t)
t

= ∫0 Ca (τ) ∙ [BF ∙ R(t − τ)]dτ [Equation 1.23]
where R(t) is the impulse residue function (IRF) defined as the fraction of contrast that is
contained in the tissue as a function of time after the contrast is injected instantaneously.
R(t) is scaled by BF and defined as:
1
R(t) = {
Ee

−

0≤t≤

BF∙E
BV
(t− )
ve
BF

t>

BV
BF

BV

[Equation 1.24]

BF

𝑣𝑒 is the distribution volume of extravascular extracellular space per unit volume of tissue,
and E is the extraction fraction that is described as the fraction of contrast that leaks into
the interstitial space and is defined as:
PS

E = 1 − e− BF

[Equation 1.25]

CTP measurements consist of two phases of imaging acquisition after a bolus injection of
the iodinated contrast agent based on the BF-scaled IRF. The first phase involves rapid
image acquisitions (1 – 2 s per image) capturing the first wash-in and wash-out process of
the contrast agent to calculate BF and BV. BF can be solved by devolving the Ca(t) with
Ct(t) using Equation 1.23, and BV is estimated as the area under the IRF during the first
phase. The second phase consists of less frequent acquisitions (10 – 15 s per image) to
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calculate PS. E is the height of IRF at the beginning of the second phase, and PS can then
be solved from Equation 1.25 with known E and BF.

1.6 Positron emission tomography
PET imaging is based on the interaction between an electron and a positron arising from
the decay of a positron-emitting radionuclide. A small dose of radionuclide is injected into
patients prior to a PET scan. The radionuclide will continue to decay as it moves though
the blood stream until it reaches the designated target, releasing positrons that collide with
nearby electrons in a process known as positron-electron annihilation. These interactions
will emit a pair of 511 keV gamma photons that exit the body and are detected by the PET
scanner [65–67].

1.6.1 PET basics:
Commonly used positron-emitting radioisotopes (such as

11

C,

13

N,

15

O and

18

F) are

produced locally in a cyclotron due to their short half-life. These radioisotopes are then
used to synthesize various radio-labeled compound or radiotracers based on the clinical
need. The two photons will be detected by two detectors on the ring of PET scintillation
detectors, the signals from the detectors are then amplified, digitized, and the digitized
values histogrammed using a multi-channel analyzer. A coincidence window of ∆t will be
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set, where ∆t defines the temporal or timing resolution (3-4 ns) for the two events to be
registered as coincidence event. The acquired signal is stored in a list-mode data set

Figure 1.9: Schematic of detecting coincidence events for two detectors. Signal 1 from
Detector 1 results in a trigger pulse 1 which sets the start of check the coincidence window.
Signal 2 from Detector 2 results in a trigger pulse 2. A coincidence circuit will check for
coincidence between the pulse 2 and pulse 1 (Δt = t2 – t1) and the coincidence window
(timing resolution).

23

(containing detector locations and detection time for each coincidence event), processed
into sinograms, and reconstructed into volumes portraying the distribution of PET tracer
averaged over a period of time in a single frame or multiple frames. For a 3D acquisition,
each frame of data can be binned into a set of N2 oblique sinograms between detector rings,
where N is the number of detector rings and a sinogram is a graph that plots the number of
coincidences detected for each possible detector pair. Sinograms are corrected for random
and scatter emission events before PET images are reconstructed using a filtered back
projection reconstruction [68] or iteratively by comparing them to the sinograms of
different theoretical volumes. For instance, the 3D ordered-subset expectation
maximization followed by fast maximum a posteriori (OSEM3D/FMAP), works by
dividing the measured sinograms into non-overlapping subsets and using only one subset
at a time to minimize the difference between the measured subset and a theoretical subset
that is based on the forward projection of a model image (OSEM3D), and then by
maximizing a function that penalizes images that do not fit the data well (MAP) [69].
The standardized uptake value (SUV) is most commonly used to semi-quantify clinical
PET signals with a single late-time-point activity normalized by the injected activity and
the weight of the subject [66], calculated as:
SUV =

Activityregion of interest
Activityinjected ÷ Weight

[Equation 1.26]

Depending on the kinetics of the 18F-labeled tracer, static PET images may be acquired 30
to 120minutes after injection to disregard the perfusion effect of the tracers. PET images
can also be analyzed using tracer kinetic modelling: kinetic modelling accounts for the
effect of tracer pharmacokinetics (tracer delivery, clearance and target reaction), as a result,
it can provide more accurate information about the target concentration (measured by
volume of distribution) and influx/efflux rate constants [70,71].

1.6.2 [18F]-Fluorodeoxyglucose (FDG)
FDG is the most commonly used PET radionuclide for cancer imaging. The structure of
FDG is shown in Figure 1.10a. FDG is similar in structure to glucose, replacing the

24

hydroxyl group at the 2nd carbon location with an

18

F, and it can be transport into cells

using the same glucose transporters (GLUTs). After a bolus injection of FDG (in pmol),
FDG will be transported into the cells and go through the first step of glycolysis in the
cytoplasm, phosphorylated by hexokinase to FDG-6-phospate (FDG6P), without
continuing the rest of the glycolytic steps (as shown in Figure 1.10a). As a result, FDG6P
will be trapped inside of the cells and provide signals which can then be detected with PET.
The Patlak graphical analysis method assumes that the pharmacokinetics of FDG is
irreversible [72], i.e. FDG6P will be trapped inside the cells after FDG is phosphorylated.
However, a recent study has shown the reversibility of FDG6P trapping, where FDG6P
could be fed into the pentose phosphate pathway by glucose-6-phosphate dehydrogenase,
and in turn be transported out of the cell by GLUTs [73]. A Logan graphical analysis
method could be employed to better model FDG pharmacokinetics, as it assumes reversible
binding for radiopharmaceuticals [74]. Cancer cells are known to over-rely on glycolysis
and have a higher glycolytic activity compared to normal mammalian cells [3,5,66,75],
therefore, FDG can provide information on cancer glycolytic metabolism at a cellular level.

1.6.3 PET kinetic modeling
Tracer kinetic modelling has the practical purpose of condensing dynamic information into
parameters describing the primary processes that affect tracer distribution. PET
experiments can capture the dynamic changes in tracer concentration which do not get
distributed instantaneously according to the quantity of the target reaction. Instead, the
tracer dynamically experiences two or more processes including delivery, clearance, and
the target reaction. As a result, the tracer undergoes dynamic change, and this can be seen
by plotting the tracer radioactivity concentration against time to construct what is
frequently referred to as a time-activity-curve (TAC).
To model the pharmacokinetic process of FDG, an irreversible two-tissue three
compartment (2T3C) system [70,76] is commonly used as shown in Figure 1.10b.
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FDG is transferred from plasma (first compartment) to the extravascular space including
the extracellular space of the tissue of interest (second compartment) with the rate constant
K1 (mL/min/mL of tissue), and the reverse rate constant k2 (min-1). FDG is then transported
from the second compartment to the intracellular space in the tissue of interest where it is
phosphorylated by hexokinase to FDG-6-phosphate (FDG6P) with the rate constant k3
(min-1), FDG6P is trapped in the intracellular space without going through the subsequent
steps of glycolysis.
FDG studies can be analyzed using the compartmental model with three rate constants and
the combination of the rate constants or the net transfer rate (Ki) can be found [77]:
Ki =

K1 × k 3
k2 + k3

[Equation 1.27]

Figure 1.10: a) The chemical structure of 18F-FDG and its metabolism after entering the
cell, it will go through the first step of glycolysis and be phosphorylated to 18F-FDG-6-P
and is subsequently trapped inside the cell. b) A schematic of the 2T3C model for 18F-FDG,
Cp(t) represent the radioactivity in the plasma as a function of time, CND(t) represents the
activity of free 18F-FDG after entering the brain but before being trapped in the cells as a
function of time. CS(t) represents the activity as a function of time after 18F-FDG enters
and is trapped inside the cell.
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To simplify the 2T3C model estimation, Patlak graphical analysis was developed as a
model independent graphical analysis method to estimate the net transfer rate for tracers
with irreversible bindings i.e. without a reversible component [72,78]. An assumption
needs to be met in order to use Patlak analysis: all reversible compartments must be in
equilibrium with plasma, i.e. the concentration of radiopharmaceutical used in plasma and
in the reversible tissue compartments must remain stable. The apparent distribution volume
that is the ratio of tissue time-activity curve (TAC(t)) and arterial input function (AIF(t)),
is plotted against the normalized plasma integral which is the ratio of the integral of AIF(t)
and the AIF(t) as shown in Equation 1.28.
CROI (T)
AIF(T)

T

= Ki ×

∫o AIF(t)dt
AIF(T)

+ Int [Equation 1.28]

Where T denotes the time interval from the start to a specific frame, and Int denotes the yintercept. When the equilibrium is reached, i.e., after the distribution volume of reversible
compartments is effectively constant, the Patlak plot becomes linear, and the slope of the
linear phase is Ki which can be in turn converted to the metabolic rate of glucose (MRGlu)
using Equation 1.29:
MRGlu = K i ×

CGlucose Plasma
LC

[Equation 1.29]

Where Cglucose plasma is the concentration of glucose in the plasma, and LC is the lumped
constant, a conversion factor to obtain estimation of the glucose metabolic rate from the
glucose analog FDG [78,79]. Kinetic modeling with Patlak graphical analysis or
compartmental modeling allows quantitative assessment of glucose utilization from FDG
[79,80].

1.8 Objectives and Hypothesis
Chapter 2: To evaluate glucoCEST as a surrogate biomarker of tumor perfusion and/or
tumor glycolysis, we compared various well-defined in vivo perfusion and glycolysis
measurements in the C6 rat glioma model. Tumor perfusion maps such as blood flow (BF),
blood volume (BV), and permeability surface-area product (PS) were derived with
computed tomography perfusion (CTP) measurements acquired during a bolus injection of
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iodinated contrast agent (Isovue). Glucose metabolism was evaluated with positron
emission tomography (PET) and 18F-fluorodeoxyglucose (FDG), a glucose analogue which
is phosphorylated in the cell but does not go through subsequent steps of glycolysis.
Anaerobic glycolysis was measured with MR spectroscopic imaging (MRSI) after an
injection of hyperpolarized [1-13C]pyruvate.
We hypothesized that glucoCEST measurements of the change in glucoCEST signal during
glucose infusion comparing to baseline (∆CEST) is directly proportional to perfusion
measurements. Tumor perfusion measurements of PS were also found to be directly
proportional to tumor glycolytic measurement of Lac:Pyr. These results were published in
Molecular Imaging and Biology:
Q. Qi et al., Multimodality In Vivo Imaging of Perfusion and Glycolysis in a Rat Model of
C6 Glioma, Mol Imaging Biol. 2021, 23: 516-526, DOI: 10.1007/s11307-021-01585-1.
Chapter 3: This experiment aimed to explore the relationship between tumoral and
peritumoral pHi and the change in pHi after a glucose infusion using AACID CEST MRI,
and tumoral glycolytic activity measured using FDG-PET and hyperpolarized [113

C]pyruvate MRSI.

We hypothesized that tumoral and peritumoral pHi are inversely proportional to tumor
glycolysis measurements; and the change in tumoral and peritumoral pHi induced by
glucose infusion are directly proportional to tumor glycolysis measurements. These results
were submitted to Molecular Imaging in Biology:
Q. Qi et al., Glucose Infusion Induced Change in Intracellular pH and Its Relationship with
Tumor Glycolysis in a C6 Rat Model of Glioblastoma. Mol Imaging and Bio, submitted in
November 2021.
Chapter 4: In this chapter we explored the feasibility of measuring tumor intracellular pH
and extracellular pH simultaneously with AACID and acidoCEST respectively after a pH
change was induced by a glucose injection. We also evaluated the correlations between
tumor pH environments and tumor glycolysis measurements.
We expected that the change in pHi and pHe can be detected in vivo with CEST MRI, and
we hypothesized that tumor pHi is directly proportional to tumor glycolytic activity; and
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tumor pHe is inversely proportional to tumor glycolytic activity. These results will be
submitted in early 2022 to an appropriate journal:
Q. Qi et al., Evaluation of the Change in Tumor Intra-/Extracellular pH Environment
Induced by Glucose Injection and its Relationship with Tumor Glycolysis in a C6 Rat
Model of Glioblastoma. To be submitted.
Chapter 5: In this concluding chapter, we discuss the key findings, limitations, and future
directions to better investigate cancer perfusion, glycolysis, and its pH environment.
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Chapter 2
Multimodality In Vivo Imaging of Perfusion and Glycolysis in
a Rat Model of C6 Glioma
Qi Qi, Matthew S. Fox, Heeseung Lim, Robert Bartha, Lisa Hoffman, Timothy J. Scholl,
Ting-Yim Lee, Jonathan D. Thiessen
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Abstract
Chemical exchange saturation transfer MRI using an infusion of glucose (glucoCEST) is
sensitive to the distribution of glucose in vivo; however, whether glucose contrast
enhancement (GCE) from glucoCEST is more related to perfusion or glycolysis is still
debatable. In this Chapter, we compared glucoCEST to computed tomography perfusion
(CTP), [18F] fluorodeoxyglucose positron emission tomography (FDG-PET), and
hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy imaging (MRSI) in a C6
rat model of glioma to determine if glucoCEST is more strongly correlated with
measurements of perfusion or glycolysis. This study determined that glucoCEST is more
strongly correlated to measurements of perfusion than glycolysis. GlucoCEST
measurements have additional confounds, such as sensitivity to changing pH, that merit
additional investigation.

2.1 Introduction
Glioblastoma multiforme (GBM) is both the most common and the most aggressive type of
malignant brain tumor. Regardless of technical advances, the median survival period for
patients who are diagnosed with GBM, remains approximately 12-15 months [1].
Angiogenesis, the formation of blood vessels, is regarded as one of the hallmarks of GBM.
These newly formed vessels facilitate the delivery of nutrients such as glucose to cancer
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cells, contributing to the observed increase in tumor metabolism (glycolysis) and ultimately,
tumor proliferation [2]. Inevitably, measurements of tumor perfusion and glucose
metabolism are interrelated, and are important imaging biomarkers for predicting tumor cell
proliferation and assessing treatment response. Chemical exchange saturation transfer
(CEST), a magnetic resonance imaging (MRI) technique, may be used to monitor both
tumor perfusion and glucose metabolism [3]. In particular, CEST is sensitive to endogenous
glucose, potentially allowing us to monitor the change in metabolite concentration over
time after an injection of glucose (glucoCEST) [4,5]. Originally, researchers proposed that
the change in concentration monitored using glucoCEST in the tumor region was associated
with glucose metabolism [6,7]. However, recent studies have shown that these changes are
also sensitive to tumor perfusion [8,9].
To evaluate glucoCEST as a surrogate biomarker of tumor perfusion and/or tumor
glycolysis, we compared various well-defined in vivo perfusion and glycolysis
measurements in the C6 rat glioma model. Tumor perfusion maps such as blood flow (BF),
blood volume (BV) and permeability surface-area product (PS) were derived with
computed tomography perfusion (CTP) measurements acquired during a bolus injection of
iodinated contrast agent (Isovue). Glucose metabolism was evaluated with positron
emission tomography (PET) and 18F-fluorodeoxyglucose (FDG), a glucose analogue which
is phosphorylated in the cell but doesn't go through subsequent steps of glycolysis. Aerobic
glycolysis was measured with MR spectroscopic imaging (MRSI) after an injection of
hyperpolarized [1-13C]pyruvate.
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2.2 Methods

Figure 2.1: a) Study overview. Day 0 corresponds to the tumor cell implantation. A CT
perfusion check was performed on Day 7 to monitor if the tumor had reached optimal size
(diameter > 4 mm). An FDG-PET acquisition followed by CT perfusion experiment was
13

carried out between Days 11 and 13. The glucoCEST experiment and hyperpolarized Cpyruvate MRSI took place on the following day (Days 12 to 14). b) Dynamic CEST
experiment. There were three CEST acquisitions: a baseline CEST acquisition (Pre), a
second CEST acquisition during the first 30 minutes of glucose infusion (During 0-30 min)
and a final CEST acquisition during the last 30 minutes of glucose infusion (During 30-60
min).
The experimental timeline is shown in Figure 2.1a. In short, C6 glioma tumor cells were
implanted on Day 0. A CT perfusion check was performed on Day 7 to check if the diameter
of the tumor has reached 4 mm [10-12]. FDG-PET followed by CT perfusion acquisition
were performed between Day 11-13 after C6 cell implantation. GlucoCEST MRI followed
by hyperpolarized [1-13C]pyruvate MRI experiments were performed on the next day
immediately prior to euthanization. All imaging experiments took place within a span of 24
hours for each animal: FDG-PET and CT perfusion in the afternoon/evening, followed by
9.4T MRI (glucoCEST) and 3T MRI (hyperpolarized MRSI) in the morning/afternoon of
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the subsequent day. All procedures were performed in compliance with the Canadian
Council for Animal Care and approved by the Western University Animal Care Committee.

2.2.1 C6 glioma model
Male Wistar rats (Charles River, Canada, age 8 to 10 weeks at surgery) weighing on average
401 ± 42 g (N = 11) were used in this study. The animals were induced with 5% isoflurane
and were maintained at 2-3% for all surgical and imaging procedures.
C6 glioma cells (CCL-107, American Type Culture Collection, Manassas, VA) were
cultivated in F12k 15% horse serum, 2.5% bovine serum, and 1% penicillin-streptomycin.
Animals were placed into a stereotactic surgical frame during C6 glioma cell implantation.
The animals were anesthetized with 2% isoflurane and were injected with Metacam
(Boehringer Ingelheim Vetmedica Inc, Duluth, US, 10 mg/kg). The bregma was exposed
after a scalp incision; a 1-mm-diameter burr hole was drilled at a point 1 mm anterior and
3 mm right of the bregma. A total of 106 C6 glioma cells suspended in 10 µL were slowly
injected over a period of 5 minutes at a depth of 3–4 mm from the skull surface with a
Hamilton syringe. The burr hole was sealed with bone wax, and the scalp was closed with
sutures. The subjects were recovered and returned to animal care housing where they
received an additional subcutaneous injection of Metacam (10mg/kg) 12 hours after
surgical recovery.

2.2.2 CT perfusion imaging and analysis
Detailed CT perfusion acquisition and analysis procedures can be found in previous
research publications [10,11]. In short, a non-contrast CT scan was performed prior to the
perfusion scan to identify sixteen slices covering the entire brain with each section 1.25 mm
thick (GE Discovery RCT). CT perfusion data were acquired over two back-to-back time
periods. A fine temporal resolution (1.4 s intervals) was used during the first time period
(32 s duration) and a coarse temporal resolution (15 s intervals) was used in the second
period (165 s duration). 2-3 s after the start of the first phase a bolus of contrast (Isovue,
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Bracco Diagnostics Inc, Vaughan, Canada, 300 mg iodine/mL, 2.5 mL/kg body weight)
was injected into a lateral tail vein at a rate of 0.13 mL/s using a syringe pump (New Era
Pump Systems, Inc, Farmingdale, NY, USA). The scan parameters were 80 kVp, 120 mAs,
10 cm field-of-view with a high-definition bone filter. A change of CT number as a function
of time can be measured using the dynamic series of CTP images. The subjects were able
to proceed to the subsequent experiments when the axial diameter of the tumor reached 4
mm [11,12]. The CT perfusion measurements that were used in the perfusion analysis were
acquired Day 11-13 on a clinical CT scanner (Discovery 750 HD, GE Healthcare,
Waukesha, WI) after a 75-minute dynamic FDG-PET acquisition.
CT Perfusion 5 (GE Healthcare) was used to generate maps of BF, BV, and PS. The time
attenuation curve (TAC) from the carotid artery was selected as the arterial input. The
arterial TAC was deconvolved with tissue TACs measured from 2×2 pixel blocks of CT
images using the Johnson-Wilson model to calculate maps of BF, BV, and PS [12,13]. As
described in Chapter 1, the tissue-enhancement curve can be expressed as the convolution
between the blood flow-scaled impulse residue function (IRF), BF·R(t), and the arterial
TAC, Ca(t). The shape of the BF-scaled IRF has two distinct phases, and it is solved by
deconvolving the arterial TAC with the tissue-enhancement curve. The plateau of the BFscaled IRF defines the BF, while the area under the first phase of the BF-IRF is the BV.
The second phase of the BF-scaled IRF starts at the height of the extraction fraction, which
is the fraction of contrast agent that leaks into the interstitial space. The second phase of the
BF-scaled IRF decays with time, and PS can be calculated as PS = −BF × ln(1 − E), E is
the extraction fraction.

2.2.3 FDG-PET imaging
The FDG-PET acquisition took place 11-13 days after the surgery on a small animal PET
system (Inveon DPET, Siemens Healthineers, Knoxville, TN, USA). The blood glucose
level of each subject was tested using a glucometer prior to FDG-PET acquisition
(CONTOUR meter, Ascensia Diabetes Care, Parsippany, NJ, USA). A 75-minute emission
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scan was performed with a timing window of 3.432 ns and 350-640 keV discrimination
energy range. Longitudinal PET data were binned into successive time intervals comprised
of 10 frames of 30 s, 5 frames of 60 seconds, 10 frames of 300 seconds and 1 frame of 900
seconds, totaling 75 minutes. An iterative, 3D ordered subset expectation maximization
(OSEM3D) reconstruction was used to generate dynamic images for all frames with 2
iterations and 18 subsets. Approximately 30 s after the acquisition had started, a bolus of
18

F-FDG (31.5 ± 3.1 MBq) was injected through a lateral tail vein. Anatomical CT images

acquired after the PET acquisition were used to generated attenuation corrected PET
images. The CT images were co-registered with the PET images using ASIPro (Siemens
Healthineers, Knoxville, TN, USA). The co-registered CT images were used to generate a
mu-map by converting Hounsfield units into linear attenuation coefficients for 511 keV
gamma rays. The mu-map was then converted into an attenuation sinogram. The PET
images were reconstructed using the attenuation sinogram to create the attenuation
corrected PET images.
Standardized uptake values (SUV) were calculated using the last 15 minutes of the dynamic
PET images as a surrogate for glucose metabolism. SUV was defined as SUV = Activity
Concentration of ROI/ (Injected Dose / Weight of the Subject) [14].

2.2.4 Dynamic glucoCEST imaging
MRI was acquired on a 9.4-T small animal MRI (Agilent, Palo Alto, CA, USA) the day
after PET/CT (12 – 14 days after the surgery). Axial T2-weighted images using a 2dimensional fast spin-echo (FSE) sequence (repetition time, TR = 3000 ms; echo time, TE
= 10 ms; effective TE = 40 ms; echo train length = 4; number of slices = 29; slice
thickness = 1 mm; field-of-view, FOV = 3.84 x 3.84 cm; matrix size = 128 × 128;
acquisition time ≈ 3 min) were acquired first to locate the slice axially that contained the
largest tumor cross-section. CEST spectra were acquired using a continuous wave presaturation pulse (saturation time, TS = 5 s; B1 saturation pulse amplitude = 1.6 μT; offset
frequency pulse alternated between negative and positive, from -5/+5 to 0 ppm with 0.2
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ppm steps) preceding a series of FSE images acquired on the axial slice that contained the
largest tumor cross-section (TR = 3 s, effective TE = 40 ms, echo train length = 32, slice
thickness = 2 mm, FOV = 3.84 x 3.84 cm FOV, matrix size = 128 x 128; acquisition time
≈ 30 min). Three spectra were obtained from three consecutive 30 min CEST acquisitions.
The first CEST spectrum was acquired prior to a 20% D-glucose infusion. A bolus of 20%
D-glucose solution (0.3 g/kg) was injected at the end of the first spectrum acquisition,
following by a 60-minute constant infusion of the same 20% D-glucose solution (1.5
g/kg/hour). The acquisition of the second and third CEST spectra corresponded to the first
and second half of the constant infusion of glucose, respectively. The CEST imaging
workflow is illustrated in Figure 2.1b.
All CEST data were analyzed using MATLAB 2018b. A mask of the brain was delineated
using the T2-weighted MR images and applied to the CEST images. A smoothing spline
with a fitting parameter of 0.998 was used to generate Z-spectra at each pixel using all 53
CEST images. B0 correction was performed by shifting the frequency associated with the
Z-spectra minima to 0 ppm. A magnetization transfer ratio asymmetry (MTRasym)
spectrum [15] at each pixel was calculated as shown in Equation 2.1.
𝐌𝐓𝐑 𝐚𝐬𝐲𝐦 =

𝐒(−∆𝛚) −𝐒 (∆𝛚)
𝐒𝟎

[2.1]

The area under the curve (AUC) was calculated using MTRasym (AUCMTR) values from
1.2 to 2.8 ppm [6] and the relative change after glucose infusion was calculated as ∆CEST
(see Equation 2.2). Note that AUC(during-infusion) corresponds to the last 30 minutes of the
glucose infusion (the third CEST spectra), as a different imaging protocol was used in some
of the experiments while the blood glucose was still increasing in the first 30 minutes of the

∆CEST =

glucose infusion.

𝐀𝐔𝐂(𝐝𝐮𝐫𝐢𝐧𝐠−𝐢𝐧𝐟𝐮𝐬𝐢𝐨𝐧) − 𝐀𝐔𝐂(𝐩𝐫𝐞−𝐢𝐧𝐟𝐮𝐬𝐢𝐨𝐧)
𝐀𝐔𝐂(𝐝𝐮𝐫𝐢𝐧𝐠−𝐢𝐧𝐟𝐮𝐬𝐢𝐨𝐧)

[2.2]
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2.2.5 Hyperpolarized [1-13C]pyruvate
Detailed hyperpolarization and imaging procedures can be found in Lim et al. [16]. Rats
were transported to a GE Discovery MR750 3.0-T MRI (General Electric Healthcare,
Waukesha WI, U.S.A.) under anesthesia with 2% isoflurane immediately after the glucose
CEST experiment. An FSE sequence (80 x 80 mm FOV, 0.3-mm in-plane resolution, 3-mm
slice thickness, TR = 4000 ms, TE = 85 ms, 16 echo trains and 9 averages) was used to
acquire axial T2-weighted 1H images which were later used to determine the axial slice(s)
that contained the tumor and located at the approximate the same location using the CEST
slice information. ProHance gadolinium contrast agent (Bracco Diagnostics, Monroe
Township, NJ, USA) was added at a concentration of 1 mM to [1-13C]pyruvic acid (Sigma
Aldrich, Miamisburg OH, USA), and the sample was hyperpolarized using a HyperSense
dynamic nuclear polarizer (DNP, Oxford Instruments, Abingdon, UK). The resulting
buffered hyperpolarized [1-13C]pyruvate solution (80 mM) had a final volume of ~4 ml with
a pH of 7.4 at 37℃. A 3-ml volume of hyperpolarized [1-13C]pyruvate solution was rapidly
transferred to the MRI where it was injected through a lateral tail vein of the rat in a single
12-second bolus. After waiting a further 13 seconds for circulation and metabolism,
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spectra in the axial plane (12 x 12 spectral imaging matrix, TR=80 ms, bandwidth = 5 kHz,
2048 pts, flip angle = 10˚) were acquired using a 2D chemical shift imaging with a free
induction decay, chemical shift imaging (FID-CSI) pulse sequence (60 x 60 mm FOV, slice
thickness approximately equal to the tumor extent). One FID-CSI with 144 spectra was
acquired in each animal with a total scan time of 12 seconds. Regional maps of the ratio of
lactate to pyruvate (Lac:Pyr) were calculated using a customized MATLAB script [16]. The
animal was euthanized immediately after the experiment.

2.2.6 Benchtop blood glucose measurement
The blood glucose change was measured by sampling blood from a rat tail artery (weight =
508 g) with a glucometer (Contour 7152B, Bayer HealthCare, Leverkusen, Germany) on
the benchtop using the same glucose infusion protocol as the glucoCEST experiment.
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Baseline blood glucose was measured before the injection of 20% glucose solution (0.3
g/kg) and the start of a 60-min constant infusion (1.5 g/kg). The blood glucose of the subject
was measured every 5 minutes after the start of glucose infusion.

2.2.7 ROI selection and image registration

Figure 2.2: Example images and ROIs in a single rat. A T2-weighted 9.4 T MR image
(T2W) was used as a reference to co-register CT perfusion maps (BF, BV, PS), FDG-PET,
CEST maps (AUCMTR), and hyperpolarized [1-13C]pyruvate MRSI (Lac:Pyr). The T2W
image was subsequently used to delineate tumor (red dotted line) and contralateral brain
tissue (blue dotted line), with the same ROI applied to all imaging measurements.
Tumor volume was measured on both imaging days using CT perfusion and T2-weighted
MRI datasets, respectively. T2-weighted MRI was used as guidance for manual delineation
of tumor and contralateral brain regions. All voxels that contained tumor were included in
the tumor ROIs. The T2-weighted MRI was also used as a reference to co-register the CT
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perfusion, CEST, FDG-PET and hyperpolarized [1-13C]pyruvate images using 3D Slicer
(www.slicer.org). Manual rigid registration relied on anatomical landmarks identified in
both T2-weighted images (e.g. major white matter features such as the corpus callosum,
ventricles, and brain surface), features in the anatomical and perfusion CT (tumour, brain
surface, and skull), and uptake in the FDG-PET volume (tumour uptake and normal uptake
in the brain, Harderian glands, and surrounding tissue). The T2-weighted image from the
9.4T MRI was subsequently used for ROI delineation and applied to all of the co-registered
parameter maps (CEST, MRSI, CTP, and FDG-PET). The average BF, BV and PS values
from CT perfusion measurements; average ∆CEST measurement from glucoCEST; SUV
from FDG-PET; and Lac:Pyr ratios from hyperpolarized [1-13C]pyruvate MRSI in tumor
and contralateral brain regions were extracted. An example of registered images and ROIs
are shown in Figure 2.2.

2.2.8 Statistical analysis
Paired T-tests were used to compare the similarity of CT perfusion, CEST, FDG-PET and
hyperpolarized [1-13C]pyruvate measurements between the tumor and contralateral brain
regions. Paired T-tests were also performed on the voxel-wise AUCMTR values in the tumor
pre-infusion and during-infusion in order to determine significant changes in AUCMTR
during glucose infusion in each subject. The Pearson correlation between average tumoral
CT perfusion parameters, ∆CEST measurement from glucoCEST, SUV from FDG-PET
and Lac:Pyr ratios from hyperpolarized [1-13C]pyruvate MRSI were evaluated using IBM
SPSS version 22. A P value ≤ 0.05 was considered statistically significant.

2.3 Results
2.3.1 Tumor size
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As shown in Figure 2.3, the average tumor volume on the day of PET and CT perfusion
measurements was 98.4 ± 37.5 mm3 (measured using PS and contrast-enhanced images
from CT perfusion), and the average tumor volume on the day of CEST and hyperpolarized
[1-13C]pyruvate measurements was 99.4 ± 39.5 mm3 (measured in 9.4T T2-weighted MRI),
with no significant difference in volume between the two imaging days based on a paired
t-test (P = 0.54).

Figure 2.3: Average tumor size on first imaging day for PET and CT perfusion
experiment and the next day for glucoCEST and hyperpolarized [1-13C]pyruvate. No
statistical significance in tumor size were found between these two subsequent
imaging days (P = 0.54). Error bars = standard deviation

2.3.2 Blood glucose measurements
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Benchtop measurements of blood glucose as a function of time during the glucose infusion
protocol are plotted in Figure 2.4. The baseline blood glucose of the subject was 7.3
mmol/L and slowly increased to >20 mmol/L during the 60-minute constant infusion.
Blood glucose was 7.6 ± 1.8 mmol/L prior to the FDG-PET and CT perfusion measurements
and 6.7 ± 1.3 mmol/L prior to the CEST and hyperpolarized [1-13C]pyruvate measurements.

Figure 2.4: An illustrative example of blood glucose change during the 60min constant infusion. Time 0 was defined as the time at the start of constant
infusion of 20% glucose solution (1.5 g/kg) and after a bolus of 20% glucose
solution (0.3 g/kg) was injected.
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Figure 2.5: Illustrative examples of two different trends observed from the dynamic
glucoCEST measurements: a) expected and b) unexpected change in AUCMTR. The
expected trend was observed in 5 subjects and is shown in c), where during-infusion
AUCMTR values are significantly higher than pre-infusion AUCMTR. The unexpected trend
was observed in 6 subjects and is shown in d), where during-infusion AUCMTR is
significantly lower (n = 5, grey-dotted line) than or is not significantly different (n = 1, red
line, P = 0.46) from pre-infusion AUCMTR. Error bars = standard deviation.

2.3.3 Dynamic CEST trends
No significant change in applied frequency shifts (P = 0.52) was found between pre- (-0.09
± 0.05 ppm) and during glucose infusion (-0.10 ± 0.04 ppm). Two different trends were
observed in the dynamic CEST results (Figure 2.5). A significantly increased AUCMTR in
the tumor region at 30-60 minutes during-infusion compared to the pre-infusion AUCMTR
was denoted as an expected trend (n = 5). Significantly decreasing (n = 5) or no significant
change (n = 1) in AUCMTR in the tumor region was denoted as an unexpected trend.

2.3.4 Tumor vs. contralateral brain tissue
After comparing CEST, perfusion and glycolysis measurements: no statistically significant
difference was found in BF and ∆CEST between tumor and contralateral brain tissue (P =
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0.069 and 0.45 respectively) as shown in Figure 2.6a and 2.6f (the pixel-wise ∆CEST
values in contralateral region that were more than 2 standard deviations away from the
mean were discarded as noise); statistically significant increases in BV (P < 0.05), PS (P
< 0.001), SUV (P < 0.001) and Lac:Pyr (P < 0.001) were found in the tumor region vs.

Figure 2.6: Mean values from ROIs defined in both tumor and contralateral brain
tissue in CT perfusion maps (a) BF, b) BV and c) PS), d) FDG-PET (SUV), e)
13

hyperpolarized [1- C]pyruvate (Lac:Pyr) and f) glucoCEST (ΔCEST). A statistically
significant (P < 0.05) difference was found in BV, PS, SUV and Lac:Pyr between
tumor and contralateral brain. No statistically significant difference was found in BF
and ΔCEST between tumor and contralateral brain tissue. Error bars = standard
deviation.
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contralateral brain tissue as shown in Figure 2.6b–e. The tumor AUCMTR in both pre- and
during-infusion were significantly higher than the contralateral side (P < 0.001) as shown
in Figure 2.7.

Figure 2.7: Mean values from ROIs defined in both tumor and contralateral brain tissue
in AUCMTR pre- and During-infusion (30-60 min). A statistically significant (P < 0.05)
difference was found between tumor and contralateral side in AUCMTR pre- and during
glucose infusion.

2.3.5 CEST vs. perfusion and glycolysis
∆CEST measurements had statistically significant and strong correlations with CT
perfusion measurements of BV (0.74, P = 0.01) and PS (0.55, P = 0.04) however, no
statistically significant correlations were found between BF and ∆CEST (P = 0.27). The
Pearson correlation coefficients between ∆CEST and CT perfusion measurements are
shown in Table 2.1. ∆CEST was directly proportional with BV and PS as shown in Figure
2.8a and 2.8b respectively.
No statistically significant correlations between ∆CEST and glycolysis measurements using
FDG-PET or hyperpolarized [1-13C]pyruvate were found (Table 2.1).

2.3.6 Glycolysis vs. perfusion measurements
As shown in Table 2.1, statistically significant moderate correlations between FDG-PET
measurements of SUV and CT perfusion measurements of BF (0.49, P = 0.02) and PS (0.58,
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P = 0.005) were found. SUV was directly proportional with BF and inversely proportional
with PS as shown in Figure 2.8c and 2.8d respectively.

Figure 2.8: ΔCEST vs. blood volume (a) and permeability-surface area product (b). Tumor
SUV vs. blood flow (c) and permeability-surface area product (d). Tumor Lac:Pyr vs.
blood volume (e) and permeability-surface area product (f). Solid line indicates the best fit
and the dotted lines denote 95% confidence interval. Error bar = standard deviation.
Statistically significant moderate correlations between hyperpolarized [1-13C]pyruvate
measurements of Lac:Pyr and CT perfusion measurements of BV (0.57, P = 0.02) and PS
(0.75, P = 0.005) were also found (Figure 2.8e and 2.8f).
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As expected, there was a statistically significant moderate correlation between Lac:Pyr and
SUV (0.56, P = 0.038).
It is important to note that the blood glucose conditions were different prior to the two
glycolysis measurements: the average blood glucose level was 7.6 ± 1.8 mmol/L before
FDG-PET acquisition, whereas the average blood glucose level was above 33 mmol/L prior
to hyperpolarized [1-13C]pyruvate MRSI.

Table 2.1: Pearson correlation coefficients between CT perfusion (BF, BV and PS), FDG13
PET (SUV), hyperpolarized [1- C]Pyruvate (Lac:Pyr) and glucoCEST (ΔCEST)
measured in the tumor. * indicates P value < 0.05.

N = 11

BV

BF

0.15

BF

PS

0.57

0.33

PS

SUV

0.32

0.49*

0.58*

SUV

Lac:Pyr

0.57*

0.26

0.75*

0.56*

Lac:Pyr

ΔCEST

0.74*

0.24

0.55*

-0.23

0.28

2.3.7 Expected vs Unexpected group
As indicated in Table 2.2, in the expected group, a significant correlation between ∆CEST
and PS was found (0.60, P = 0.032), but no significant correlations were found between
other measurements. No significant correlations were found in the unexpected group, as
shown in Table 2.3.
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Figure 2.9: Good colocalization of the tumor region is displayed in AUCMTR and PS

maps. Similarly, co-localization of potential necrosis is shown among AUCMTR, BF and
BV maps (red arrow).

Table 2.3: Pearson correlation coefficients between CT perfusion (BF, BV and PS), FDG13
PET (SUV), hyperpolarized [1- C]Pyruvate (Lac:Pyr) and glucoCEST (ΔCEST)
measured in the tumor for the unexpected group. * indicates P value < 0.05.
N=5

BV

BF
PS
SUV
Lac:Pyr
ΔCEST

0.12
0.81
0.75
-0.10
0.54

BF
-0.29
0.36
-0.25
0.20

PS
-0.79
0.51
0.61

SUV
0.37
-0.32

Lac:Pyr
0.55

Table 2.2: Pearson correlation coefficients between CT perfusion (BF, BV and PS), FDG13
PET (SUV), hyperpolarized [1- C]Pyruvate (Lac:Pyr) and glucoCEST (ΔCEST)
measured in the tumor for the expected group. * indicates P value < 0.05.
N=5

BV

BF
PS
SUV
Lac:Pyr

-0.32
0.57
-0.64
0.11

BF
0.33
0.18
-0.18

PS
0.55
0.51

SUV
0.45

Lac:Pyr

ΔCEST

0.23

-0.18

0.60*

-0.43

0.15
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2.4 Discussion:
In this study, the association between perfusion and glycolysis was investigated in vivo in
the C6 rat model using CTP, FDG-PET, glucose CEST, and hyperpolarized [113

C]pyruvate MRSI. All imaging experiments were performed within 24 hours and the

tumor size did not significantly change within the 24-hour span.
Tumor ∆CEST values were both significantly correlated and directly proportional to CT
perfusion measurements of BV and PS. Increased BV in the tumor would correspond to a
higher blood fraction in the measurement, where glucose concentration will be the highest,
and a corresponding increase in glucose available to the tumor – both reflected by increased
∆CEST values. Tumor PS represents the leakiness of the tumor. Higher PS or leakiness
would lead to increased glucose delivery throughout the constant infusion of glucose. No
significant correlation was found between tumor ∆CEST measurements and tumor
perfusion measurements of BF. This could be due to tumor heterogeneity as brain tumors
will contain a mixture of viable, hypoxic and necrotic regions [17]. The AUCMTR maps
generated both pre- and during-infusion of glucose most strongly resembled the PS maps,
as illustrated in Figure 2.9. According to previous work, lower intensity regions on BV
and BF maps are associated with tumor necrosis [10], however, only one subject had an
AUCMTR that resembled tumor necrosis co-localized with reduced BV and BF indicative
of possible necrosis within the tumor region (Figure 2.9 a-c). Studies have shown CEST
can distinguish tumor necrosis based on decreased MTR values from amide, attributed to
decreased endogenous proteins and peptides in necrotic tissue [17, 18]. CEST
measurements from this study could potentially identify tumor necrosis more accurately
compared to our CTP measurements of BF and BV as MRI has superior soft tissue contrast
[19]. No significant correlations were found between ∆CEST and tumor glycolysis
measurements of SUV or Lac:Pyr ratio. Previous studies have suggested that D-glucose
CEST enhancement comes from plasma and extracellular/extravascular spaces [6,21],
whereas SUV and Lac:Pyr ratios will correspond to glucose transport and metabolism in
the cell. Our study provides important additional evidence that D-glucose enhanced
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∆CEST is more sensitive to perfusion changes than glycolysis. However, CEST
measurements of the immediate response during glucose infusion was missing because
CEST experiments for the first 30 minutes of the glucose infusion were performed with
two different protocols.
The tumor perfusion measurements of PS significantly correlated with glycolysis
measurements of SUV and Lac:Pyr ratio. PS or leakiness is also related to the
aggressiveness of the tumor [22]. Higher PS values (i.e. leakier tumors) are associated with
more aggressive tumors and more aggressive tumors would have a higher metabolism,
hence a directly proportional relationship was found between tumor PS and glycolysis
measurements. A moderate but significant correlation was found between tumor BF and
SUV and tumor BV and Lac:Pyr ratio. Higher tumor blood flow and blood volume could
indicate increased vascularity, allowing more nutrients to be transferred to the tumor for
glycolysis. Due to the sequential design of the study, glucose conditions before FDG-PET
(normoglycemic) were distinct from the hyperpolarized [1-13C]pyruvate experiment
(hyperglycemic) since it was conducted on the next day and immediately followed the
glucose CEST experiment, as a result, Lac:Pyr and SUV provided different glycolysis
measurements. In a recent study by Hundshammer et al. investigating a subcutaneous
breast cancer model in rats, there was moderate correlation between SUVmean and the
Lac:Pyr (0.41) that improved when looking at tumors with similar apparent diffusivity
coefficients (0.59) [23]. This is quite similar to the correlation we found between SUV and
Lac:Pyr (0.56) in our glioma model. Glucose and pyruvate take distinct metabolic
pathways [23], which may help explain the moderate but not strong correlation between
the two measurements. In our study, hyperglycemia, tumor glycolytic activity and lactate
production will be elevated during the hyperpolarized [1-13C]pyruvate experiment, while
mitochondrial activity and lactate oxidation will be suppressed [24, 25]. Because of the
hyperglycemic conditions, more pyruvate produced from glycolysis will be produced and
later converted to lactate acid, which may help explain the slightly stronger correlation we
found between Lac:Pyr and SUV.
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The dynamic changes of AUCMTR for all subjects are shown in Figure 2.5c. Two different
trends were found from the dynamic CEST experiment as shown in Figure 2.5a and 2.5b.
The expected trend illustrated an increasing intensity over the time of glucose infusion in
the tumor region, assuming the glucose solution would act as either a glucose metabolism
or perfusion contrast agent. An increase of glucose CEST signal in the tumor region was
expected due to the increased glucose concentration caused by a constant infusion of
glucose. Dynamic CEST maps at later infusion times appear to enhance the boundary
between necrotic and viable tumor areas as shown in Figure 2.5a. The glucose infusion
captured the leaky vessels of the viable tumor region, helping to facilitate glucose perfusion
and enhancing the contrast between viable tumor and necrotic tumor areas. In some cases,
however, the CEST map would decrease after the start of the glucose infusion (Figure
2.5b). The mechanisms for the unexpected decrease in CEST signal need to be elucidated
in future studies but may be related to the complex vascularity of the tumor, the insulin
response and/or changes in tumor pH induced by the glucose infusion.
There are several limitations for this experiment. Large tumors will often encompass the
ventricles, as a result, the ROI defined using the T2-weighted MRI will contain CSF. The
inclusion of CSF in tumor ROIs could lead to underestimation of all measurements in the
tumor regions as CSF is distinct from the contrast agent in the blood vessels and tissue.
Although histology was not performed, in a previous study using the same C6 tumor model
[10] we demonstrated the relationship between tumor perfusion measurements and tumor
hypoxia and necrosis using CT perfusion and corresponding histology data. We found that
CT perfusion measurements of BF and BV are associated with tumor necrosis and hypoxia:
regions with higher values of BF and BV representing viable tumor would surround regions
with lower values of BF and BV, which were associated with lack of vascularization due
to tumor hypoxia, necrosis or fibrosis [26]. T2-weighted MRI offers better soft tissue
contrast and resolution for tumour delineation; however, the delineated region could
potentially include non-tumor features such as edema [27]. Fasting was not done prior to
FDG-PET or subsequent glucoCEST and hyperpolarized [1-13C]pyruvate MRSI
experiments, instead, blood glucose was monitored and confirmed to be within the
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normoglycemic range prior to both imaging experiments. Although this could potentially
decrease FDG uptake [28], there is evidence that glucose loading conditions may actually
increase the conspicuity of brain tumors as normal brain uptake is decreased but gliomas
continue to utilize FDG, even in hyperglycemic conditions [29]. Fasting for an extended
period of time in small animals may also have more significant deleterious consequences
than in humans, particularly if repeated for two days in a row for both imaging experiments
[30]. Finally, in humans, FDG uptake has been shown to be approximately the same across
brain regions in hypo- and normo-glycemic conditions [31]. Ultimately, we chose to
monitor blood glucose instead of applying a fasting protocol prior to both imaging days in
this fragile animal model. Blood glucose levels were comparable prior to the start of both
imaging experiments and FDG uptake was conspicuous in the tumor relative to the
surrounding brain tissue.
Although the imaging measurements were conducted within 24 hours, they were in the
span of two days and on multiple scanners, as a result, the tumor perfusion and glycemic
environment was not identical during the measurements. During the hyperpolarized [113

C]pyruvate MRSI experiment, the subject will have received a relatively large injected

volume that includes both the previous constant infusion of glucose and a bolus of [113

C]pyruvate (approximately 6 ml total). Hypervolemia could lead to an elevated BV and

PS [32,33], however BF should not be significantly affected [32]. Renal function such as
the glomerular filtration rate will be elevated during glucose infusion [34] in order to
compensate for the volume increase. The study plan was designed to follow the radiation
safety protocol at different sites, as a result, the subjects had to be housed at our PET facility
overnight to allow the radioactivity to decay before the subjects could be transferred to the
MR facility. A hybrid PET/MR system could be used in the future to provide simultaneous
measurement under the same tumor microenvironment. Meanwhile, there are a number of
factors that could affect the CEST signal, including pH [35,36]. A lower pH environment
would be induced by hyperglycemia [37] and in turn will lead to decreased CEST signal
[6]. The glucose CEST measurements (AUCMTR) during the constant infusion of glucose
would have been underestimated due to pH reduction under hyperglycemic conditions. The
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effect of hyperglycemia on the tumor pH environment induced by a constant infusion of
glucose needs to be further investigated. One approach may be to use pH-sensitive CEST
acquisitions such as acidoCEST [38,39] or amine and amide concentration-independent
detection (AACID) [40] in conjunction with an infusion of glucose. The role that
mammalian Target of Rapamycin (mTOR) plays in glucoCEST was not identified in this
study. mTOR is upregulated in aggressive tumors and leads to elevated glucose uptake
[41]. During the last half of the infusion protocol (during-infusion), tumor metabolism is
likely to have plateaued as excess amounts of glucose are introduced into the system. In
this scenario, glucoCEST would predominantly reflect perfusion effects. Xu et al. also
concluded that glucoCEST signal originates mainly from the extravascular/extracellular
space and blood vessels [41]. There are a couple of additional limitations using D-glucose
as a contrast agent for CEST signal enhancement. The metabolism of glucose in cells will
decrease glucoCEST signal as the metabolites from glycolysis cannot be detected with
CEST [42]. In addition, insulin response to high blood glucose concentration will limit the
amount of detectable free glucose in blood [42,43].

2.5 Conclusions
Dynamic glucose CEST measurements of tumor ∆CEST was significantly correlated with
tumor perfusion measurements of BV and PS but not tumor glycolysis measurements of
SUV and Lac:Pyr, suggesting that glucose CEST imaging using ∆CEST functions
primarily as a perfusion tracer. Conversely, tumor glycolysis measurements of SUV and
Lac:Pyr were significantly correlated with perfusion measurements of PS, reflecting
increased tumor leakiness in tumors with higher glycolytic metabolism. Confounding these
results is the fact that hyperglycemia induced by a constant infusion of glucose during
dynamic CEST experiments may lead to a more acidic pH environment and give rise to
underestimation of CEST measurements. Subsequently, in approximately half of the
dynamic glucose CEST experiments, there was a drop in CEST signal post-glucose
infusion. Although glucose CEST measurements may yield additional novel information
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about tumor status, the complicated dependency of glucose CEST signal on a variety of
factors would benefit from additional in vivo mechanistic studies.
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Abstract
In the previous chapter, we explored the relationship between tumor perfusion and its
glycolytic metabolism. In this chapter, we explore the relationship between tumor
glycolysis and its intracellular pH (pHi) environment. The reliance on glycolytic
metabolism is a hallmark of tumor metabolism. Excess acid and protons are produced,
leading to an acidic tumor environment. Therefore, in this chapter, we explored the
relationship between the tumor glycolytic metabolism and tissue pH by comparing

18

F-

fluorodeoxyglucose positron emission tomography (FDG-PET) and hyperpolarized [113

C]pyruvate MR spectroscopy imaging (MRSI) to chemical exchange saturation transfer

(CEST) MRI measurements of tumor pHi. We found that pHi measurements using amine
and amide concentration independent detection (AACID) CEST MRI detected the changes
in pHi induced by glucose infusion. Significant correlations between tumor glycolytic
measurement of Lac:Pyr and tumoral and peritumoral pHi and ∆pHi reveal the intrinsic
relationship between tumor glycolytic metabolism and the tumor pH environment as well
as the peritumor pH environment.
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3.1 Introduction
Tumor pH and metabolism are intrinsically related. Changes in the tumor pH environment
as a result of metabolism could provide crucial information on its aggressiveness and
progression [1–4]. In general, the tumor extracellular pH (pHe) environment is more acidic
than intracellular pH (pHi) as a result of the overreliance on aerobic glycolysis, through
which excess lactic acid and H+ are produced and transported to the extracellular space to
maintain a more alkaline pHi, which avoids apoptosis [1,2,5,6]. pHe can be measured in
vivo using techniques such as pH probes, chemical exchange saturation transfer (CEST) in
conjunction with exogenous contrast agents, and magnetic resonance spectroscopy
imaging (MRSI) using hyperpolarized bicarbonate [3,5–7]. However, the in vivo
information on pHi is often missing as it is challenging to obtain information from the
intracellular space. Importantly, an alteration in tumor pHi could provide crucial
information about treatment response [6,10]. Previously, an infusion of glucose was found
to decrease extracellular pH in human tumor xenografts [8]. In fact, most tumors rely on
aerobic glycolysis for energy production (also known as “the Warburg effect”), resulting
in increased production of H+ and lactate acid that are extruded to the extracellular space
[4]. Tumoral and peritumoral regions are intrinsically related, with tumor metabolism also
able to alter the peritumoral pH microenvironment. pH in the peritumoral region could
potentially indicate the level of tumor activity or aggression [3]. Lower pHi in the
peritumoral region could be due to a high concentration of hydrogen ions produced by
highly active tumor cells.
A CEST MRI method based on the distinct CEST responses of the endogenous amide and
amine proton that are available in tumor intracellular space enables the measurement of in
vivo pHi [11]. Amide and amine concentration independent detection (AACID) was
developed exploiting the change in exchange rate of amide and amine protons due to
change in pHi [11]. The ratio of amide-to-amine CEST effect can be calculated and then
related to pHi [10,11], where higher AACID values are associated with lower pHi.
Tumor glycolytic metabolism can be evaluated with positron emission tomography (PET)
and 18F-fluorodeoxyglucose (FDG), a glucose analogue that is phosphorylated to FDG-6-
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phosphate (FDG6P) after the first step of glycolysis but doesn't go through subsequent
steps. As a result, FDG6P becomes trapped inside cells. Anerobic glycolysis can also be
measured with magnetic resonance spectroscopy imaging (MRSI) by monitoring the
conversion of lactose to pyruvate during anerobic glycolysis to lactate after an injection of
hyperpolarized [1-13C]pyruvate [12].
The purpose of this study was to explore the relationship between tumoral, peritumoral pHi
and the change in pHi after a glucose infusion using AACID CEST MRI, and tumoral
glycolytic activity measured using FDG-PET and hyperpolarized [1-13C]pyruvate MRSI.
Intracellular pH measurements were made following perfusion of glucose and related to
previously published measures of glycolysis [13]. We hypothesized that tumoral and
peritumoral pHi are inversely proportional to tumor glycolysis measurements; and the
change in tumoral and peritumoral pHi induced by glucose infusion are directly
proportional to tumor glycolysis measurements.

3.2 Methods
3.2.1 Experiment design
Detailed experimental protocols and procedures can be found in Chapter 2 [13]. All
procedures were performed in compliance with the Canadian Council for Animal Care and
approved by the Western University Animal Care Committee. In short, C6 glioma tumor
cells were implanted on Day 0 followed by a CT perfusion check on Day 7 to confirm
tumor growth (tumor longest axis ≥ 4 mm) [13,14]. After confirming the longest axis of
tumor had reached 4 mm, the FDG-PET experiment was performed between Day 11-13
after C6 cell implantation. MRI experiments (CEST followed by hyperpolarized [113

C]pyruvate MRSI) were performed on the next day immediately prior to euthanasia with

all imaging experiments taking place within a span of 24 hours for each animal.
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3.2.2 C6 glioma model
A detailed description of the C6 glioma model can be found in previous publications
[13,14].
Male Wistar rats (Charles River, Canada, age 8 to 10 weeks at surgery) weighing on
average 401 ± 42 g (N = 11) were used in this study. The animals were induced with 5%
isoflurane and were maintained at 2% during the surgery. A burr hole was drilled at a point
1 mm anterior and 3 mm to the right of the bregma after an incision on the skull to expose
the bregma. 1 million C6 glioma cells (CCL-107, American Type Culture Collection,
Manassas, VA) were cultured [13,15] and injected at the location of the burr hole at a depth
of 3-4 mm from the skull surface with a Hamilton syringe. The burr hole was filled with
bone wax and the incision was sutured. Animals were recovered and returned to animal
facility for housing after the surgeries.

3.2.3 FDG-PET imaging
The detailed PET procedure can be found in Chapter 2 [13]. In short, all PET acquisitions
were performed using a small animal PET system (Inveon DPET, Siemens Healthineers,
Knoxville, TN, USA). The blood glucose of each subject was measured and reported in
previous work [13] by taking blood from a lateral tail vein prior to an injection. Each
subject was injected with a bolus of 18F-FDG (31.5 ± 3.1 MBq) intravenously 30 s after the
start of the 75 min dynamic PET acquisition. The PET data was reconstructed using a CTbased attenuation correction map and an iterative, 3D ordered subset expectation
maximization with 2 iterations and 18 subsets.
Standardized uptake values (SUV) were calculated using the last 15 minutes of the PET
images as a measurement of glycolysis [13,16].
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3.2.4 Dynamic CEST imaging
A detailed description of the CEST procedure can also be found in a previous publication
[13]. The dynamic CEST MRI was acquired on a 9.4-T small animal MRI (Agilent, Palo
Alto, CA, USA) on the morning after the PET acquisition (12 – 14 days after the surgery).
MR images were acquired on a 9.4 T small animal MRI scanner (Agilent, Palo Alto, CA,
USA) equipped with a 15-cm gradient coil set of 450 mT/m strength, Bruker Avance MRI
III console with software package of Paravision-6 (Bruker BioSpin Corp, Billerica, MA).
Standard anatomical T2-weighted images were used for tumor detection. The axial T2weighted images were acquired using a 2-dimensional TurboRARE pulse sequence with
parameters: TR/TE = 5000/40 ms, FOV = 38.4 × 38.4 mm2, matrix size = 192 × 192, 31
slices with slice thickness = 1 mm. Upon initial tumor detection, a 2 mm-slice from the T2weighted images with maximum tumor coverage was selected for CEST imaging. CEST
imaging was acquired using a 2-dimensional RARE pulse sequence (TR/TE = 10000/25
ms, FOV = 38.4 × 38.4 mm2, matrix size = 96 × 96, slice thickness = 2 mm) preceded by
a continuous RF pulse with amplitude 1.5-µT and duration 4 s. The CEST images were
acquired at different saturation frequencies (-5.0 to 5.0 ppm with 0.2 ppm-increment), 1000 and 1000 ppm images were acquired as reference, total 53 images). Three consecutive
spectra were obtained with 30 min per CEST acquisition. A baseline CEST spectrum was
acquired prior to an infusion. A bolus of 20% by weight of D-glucose and saline solution
(0.3 g/kg) was injected after the baseline CEST spectrum, followed by a 60-minute constant
infusion of the same 20% D-glucose solution (1.5 g/kg/hour). The acquisition of the second
and third CEST spectra were associated with the first and second half of glucose constant
infusion with 30-minute duration each, respectively. The third CEST spectrum was denoted
as “During infusion” and used to compare with the baseline CEST spectrum to examine
the effect of glucose infusion on pHi using AACID. The CEST signal from glucose may
be not relevant to the AACID evaluation as only amine and amide resonant frequencies
were used for analysis.

3.2.5 Hyperpolarized [1-13C]pyruvate
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Detailed procedures for hyperpolarized [1-13C]pyruvate MRSI can be found in previous
publications [12,13].
Briefly, the hyperpolarized [1-13C]pyruvate MRSI experiment took place immediately after
the CEST experiment on a GE Discovery MR750 3.0 T MRI (General Electric Healthcare,
Waukesha WI, USA). An FSE sequence was used to locate and acquire an axial T2weighted MRI of the same slice used for the CEST acquisition (80 × 80 mm FOV, 0.3-mm
in-plane resolution, 3-mm slice thickness, TR = 4000 ms, TE = 85 ms, 16 echo trains,
number of averages = 9). A volume of 3 mL hyperpolarized [1-13C]pyruvate solution was
injected through a rat lateral tail vein by a single bolus in 12 s. Axial

13

C spectra was

acquired using a 2D free induction decay chemical shift imaging (FID-CSI) pulse sequence
(FOV = 60 × 60 mm, slice thickness approximately equal to the tumor extent, 12 × 12
spectral imaging matrix, TR = 80 ms, bandwidth = 5 kHz, 2048 pts, flip angle = 10°) 13 s
after injection

to complete the circulation and metabolism of hyperpolarized [1-

13

C]pyruvate. Each FID-CSI containing 144 spectra was acquired within a total scan time

of 12 s. Maps of the ratio of lactate to pyruvate (Lac:Pyr) were derived as a measurement
of anaerobic glycolytic metabolism using a customized MATLAB script [12,13]. The
animal was euthanized immediately at the end of the experiment.

3.2.6 Phantom preparation
Phantoms were made following the recipe from McVicar et al. [11] to imitate physiological
protein and glucose concentration in rodent and human brain. Bovine serum albumin
powder (BSA, Sigma-Aldrich, St. Louise, Missouri, US) and glucose powder (D-(+)glucose, Sigma-Aldrich, St. Louise, Missouri, US) were prepared in pH buffer solutions to
achieve 10% BSA and the required glucose concentrations (2.5, 4.5 and 6 mM). A series
of pH buffers were made by adding HCl and NaOH to 1x phosphate-buffered saline (PBS)
solution to obtain physiological pH levels of 6.2, 6.4, 6.6, 6.8, 7.0, 7.2 and 7.4. The pH
values were measured by using a benchtop pH meter (Accumet Basics AB15 pH meter,
Fisher Scientific, Waltham, Massachusetts, US). Three phantoms at glucose concentration
of 2.5, 4.5 and 6 mM were made to mimic extracellular tissue glucose concentrations
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during normo- to hyperglycemic conditions in rat brain [17]. Each phantom contains 7
NMR tubes (3 mm diameter, Sigma-Aldrich, St. Louise, Missouri, US) held by a custom
3D printed holder. The NMR tubes contain mixtures at pH of 6.2, 6.4, 6.6, 6.8, 7.0, 7.2 and
7.4. Phantoms were scanned using the same imaging protocol as the in vivo CEST
experiment as described above.

3.2.7 Simulation
A 7-pool model was used to simulate AACID CEST signal (based on code available at
cest.org), with the analytical solution derived from Bloch-McConnell equations as
described by Zaiss et al. [18,19]. 4 pools were associated with glucose at resonant
frequencies of 0.66, 1.29, 2.18 and 2.88 ppm (Pool B, D, E, F respectively), 1 pool was
associated with amine at 2.75 ppm (Pool G), 1 pool was for amide at 3.5 ppm (Pool H),
and the water pool was set at 0 ppm (Pool A). The macromolecule effect and nuclear
overhauser effect (NOE) were neglected from the simulation. The exchange rates at
different pH’s for glucose at 4 resonant frequencies were defined using Equation 3.1
according to Zaiss et at [18,19]:
𝐤 𝐗𝐀 = 𝐤 𝐱𝟏 ∙ 𝟏𝟎𝐩𝐇−𝟕 + 𝐤 𝐱𝟎

[3.1]

Where kBA, kDA, kEA and kFA (x = B, D, E and F) are the proton exchange rates for the 4
corresponding exchanging protons on D-glucose, and the exchange rates for amine and
𝐤 𝐚𝐦𝐢𝐧𝐞 = 𝟏𝟎𝐩𝐇−𝟒.𝟐

[3.2]

amide at different pHs were defined as Equation 3.2 and 3.3 based on McVicar et al [11].
𝐤 𝐚𝐦𝐢𝐝𝐞 = 𝟓. 𝟕𝟓 × 𝟏𝟎𝐩𝐇−𝟔.𝟒

[3.3]
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Relevant simulation parameters are listed in Table 3.1.
Table 3.1: Parameters used for the 7-pool BM simulation.
Parameter
T
1

Value
2.002 s

T2

0.2 s

B0

9.4 T

B1

1.5 μT

Glucose concentration

2.5, 4.5 and 6 mM

kB1

1467 Hz

kB0

617 Hz

kD1

3580 Hz

kD0

800 Hz

kE1

2804 Hz

kE0

669 Hz

kF1

8543 Hz

kF0

675 Hz

3.2.8 CEST imaging analysis
Custom scripts were written using MATLAB 2018b (MathWorks, Natick, Massachusetts
USA) for all CEST analysis. A mask of the brain was delineated using the T 2-weighted
MR images and applied to the CEST images. The Z-spectra were fitted with method
described in a previous publication [13], briefly, the data from each voxel was smoothed
with a smoothing spline fit of a fitting parameter of 0.998. The frequency associated with
the minima of Z-spectra were shifted to 0 ppm for B0 correction. Magnetization transfer
ratio asymmetry (MTRasym) spectra were calculated as shown in Equation 3.4.
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𝐌𝐓𝐑 𝐚𝐬𝐲𝐦 =

𝐒(−∆𝛚) −𝐒 (∆𝛚)

[3.4]

𝐒𝟎

Using the MTRasym spectra, a Lorentzian line was fitted at the visible resonance frequencies
of glucose, amine and amide. The amplitude and fullwidth half maximum (FWHM) were
obtained from these Lorentzian curves, however, the effect of NOE was not identified in
this estimation.
AACID maps were generated using a custom MATLAB script, with AACID values
calculated based on Equation 3.5 using method developed by McVicar et al [11].
𝐌𝐳(𝟑.𝟓𝟎 𝐩𝐩𝐦) × (𝐌𝐳(𝟓 𝐩𝐩𝐦) − 𝐌𝐳(𝟐.𝟕𝟓 𝐩𝐩𝐦) )

AACID = 𝐌𝐳

(𝟐.𝟕𝟓 𝐩𝐩𝐦) × (𝐌𝐳(𝟓 𝐩𝐩𝐦)

− 𝐌𝐳(𝟑.𝟓𝟎 𝐩𝐩𝐦) )

[3.5]

3.2.9 Estimation of pHi using AACID
The CEST data from the phantom was analyzed using the same method described above,
the AACID values were calculated, and the relationships between AACID and pH were
evaluated and plotted at the three concentrations of 2.5, 4.5 and 6 mM that is comparable
to brain glucose concentration during normoglycemia to hyperglycemia in vivo [17]. A
linear relationship was fitted, and the goodness-of-fit (R2) was reported between pH and
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Figure 3.1: The relationship between pH and AACID value from phantom measurements
are plotted at glucose concentrations of 2.5 (a), 4.5 (b), 6 mmol/L (c) and combined(d).
The lines of best fit are represented by the dotted line; the fitting equations, the one-way
ANOVA result and the goodness-of-fit are shown at the top right corner of each plot. The
error bars denote the standard deviation of AACID values from all pixels for individual
tube.
AACID values at these glucose concentrations as shown in Figure 3.1. Differences
between the linear correlation of pH and AACID were compared at the different glucose
concentrations to determine whether glucose concentration affected the AACID
measurements. The phantom calibration data were then used to estimate pHi from the in
vivo AACID values. The NOE effect was minimal to AACID calculation [11] in both
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phantom and in vivo experiments and neglected as AACID is independent of NOE as
shown in Equation 3.5.
The change in pHi (ΔpHi) and the baseline intracellular pH gradient (pHGi) are defined by
Equations 3.6 and 3.7 respectively:
∆𝐩𝐇𝐢 = 𝐩𝐇𝐢 (𝐃𝐮𝐫𝐢𝐧𝐠) − 𝐩𝐇𝐢 (𝐏𝐫𝐞)

[3.6]

𝐩𝐇𝐆𝐢 = 𝐩𝐇𝐢 (𝐓𝐮𝐦𝐨𝐫) − 𝐩𝐇𝐢 (𝐏𝐞𝐫𝐢𝐭𝐮𝐦𝐨𝐫)

[3.7]

3.2.10 ROI selection and image registration
A detailed description of ROI analysis and image registration can be found in a previous
publication [13]. T2-weighted MRI was used as guidance for manual delineation of tumor,
peritumor (3 mm away from the tumor boundary [15,20]) and contralateral brain regions.
All voxels that contained tumor on the T2-weighted MRI were included in the tumor ROIs.
The T2-weighted MRI was also used as a reference for manual rigid co-registration of
CEST, FDG-PET and hyperpolarized [1-13C]pyruvate images using 3D Slicer
(www.slicer.org). ROI delineations using the T2-weighted image from the 9.4 T MRI were
applied to all of the co-registered parameter maps (CEST, MRSI, and FDG-PET). The
average tumoral, peritumoral and contralateral brain pHi and ∆pHi from CEST; tumor SUV
from FDG-PET; and tumor Lac:Pyr ratios from hyperpolarized [1-13C]pyruvate MRSI
were extracted.

3.2.11 Statistical analysis
One-way ANOVA tests were performed to investigate the simple main effect of pH on
AACID and the simple main effect of glucose concentration on AACID values. A twotailed paired-sample T-test was performed to investigate the differences between tumor,
peritumor and contralateral brain pHi measurements. The Pearson correlations between
averaged tumor Lac:Pyr, SUV, and pHi for tumoral and peritumoral tissues were evaluated
using IBM SPSS version 22. A P value ≤ 0.05 was considered statistically significant.
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3.3 Results:
3.3.1 AACID vs. pH from simulation
From the three glucose concentrations ranging from normoglycemia to hyperglycemia,
inversely proportional relationships between pH and AACID were found among all three
as shown in Figure 3.2, with a higher AACID value associated with a lower pH value. R2
of the linear fitting from simulation at glucose concentration of 2.5 (a), 4.5 (b) and 6 mM
(c) are 0.99.

Figure 3.2: The relationship between pH and AACID value from simulation using the 7pool exchange model are plotted at glucose concentrations of 2.5 (a), 4.5 (b) and 6 mmol/L
(c). The lines of best fit are represented by the dotted line, and the fitting equations and the
goodness-of-fit are shown at the top right corner of each plot.

3.3.2 CEST signal at relevant metabolite resonance
frequencies
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An illustrative example of the phantom MTRasym maps at resonance frequencies of glucose,
amide and amine are shown in Figure 3.3.

Figure 3.3: MTRasym maps of phantom (6 mM) at the four main resonant frequencies of
glucose as well as the amine and amide resonant frequencies.

3.3.3 AACID value vs. pH from phantom
From normoglycemia to hyperglycemia using the same concentration as the simulation, an
inversely proportional relationship between pH and average AACID values are shown in
Figure 3.1 demonstrating a higher AACID value is associated with a lower pH under all
three glucose concentrations. An inversely proportional relationship between AACID
values and pH was found among all three glucose concentrations as shown in Figure 3.1,
the slopes, the y-intercepts, and the R2 at each concentration also are displayed. A one-way
ANOVA test indicated a simple main effect of pH on AACID value (P < 0.05). Glucose
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concentration did not indicate a simple main effect on AACID values (P > 0.05) from the
one-way ANOIVA test. As a result, the slope and intercept from the overall fitting were
used to obtain an overall estimation of pHi independent of glucose concentration (Figure
3.1d).

3.3.4 Comparison among phantom and in vivo AACID values
The in vivo AACID values displayed a similar range as AACID values acquired from
phantom measurements as shown in Table 3.2. The in vivo AACID values were calibrated
using the AACID values acquired from the phantom scan, and the resulting average pHi
using the phantom calibration.

3.3.5 pHi change during glucose infusion
The average pHi before and during glucose infusion in tumoral, peritumoral and
contralateral tissue regions are shown in Figure 3.4. Co-registered pHi maps, SUV and
Lac:Pyr images are shown in Figure 3.5.
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Figure 3.4: The average pHi before and during glucose infusion at tumoral, peritumoral
and contralateral brain regions. The asterisk denotes the significant difference (P < 0.05),
and the error bars denotes the standard deviation.

Figure 3.5: An illustrative example of registered pHi maps (pre- and during-infusion),
FDG-PET and Lac:Pyr maps overlaid on T2-weighted MRI. Tumor, peritumor and
contralateral brain regions are delineated by red-, beige- and blue-dotted lines, respectively.
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Table 3.2: Range of AACID values from in vivo and phantom measurements.

AACID range
in vivo pre-infusion

0 - 2.89

in vivo post-infusion

0 - 3.52

Phantom [2.5 mmol/L]

0 - 3.40

Phantom [4.5 mmol/L]

0 - 3.05

Phantom [6 mmol/L]

0 - 2.91

After comparing the pHi pre- and during infusion using a two-tailed paired-sample T-test,
a significant difference was found in the tumoral region (P < 0.01), whereas no significant
change was found in the peritumoral (P = 0.93) or the contralateral brain region (P = 0.30).
The tumoral pHi are significantly higher than peritumoral pHi before (P < 0.01) and during
(P = 0.04) glucose infusion. However, the contralateral brain pHi is not significantly
different from either tumoral (pre-infusion: P = 0.14; during-infusion: P = 0.89) or
peritumoral (pre-infusion: P = 0.85; during-infusion: P = 0.43) regions.
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3.3.6 Tumor glycolysis measurements vs. in vivo pHi
Significant correlations between tumor Lac:Pyr and baseline tumoral pHi (ρ = -0.58 , P =
0.04) and peritumoral pHi (ρ = -0.66 , P = 0.03) are shown in Figure 3.6 a) and b). Higher
tumor Lac:Pry is associated with lower tumoral and peri-tumoral pHi. Significant
correlation was also found between tumor Lac:Pyr and pHGi from tumor-peritumor regions
(ρ = 0.57 , P = 0.05, Figure 3.7). Higher tumor Lac:Pyr leads to higher pHi gradient (tumor
pHi > peritumor pHi).

Figure 3.6: The relationship between tumor Lac:Pyr and tumor baseline pHi (a) peritumor
baseline pHi (b), tumoral ΔpHi (c); and peritumoral ΔpHi (d). Dotted lines indicate the 95%
confidence interval, and the error bar denotes the standard deviation.
Significant correlations between tumoral Lac:Pyr and tumoral, peritumoral ∆pHi (ρ = 0.83
, P = 0.01 ; ρ = 0.76, P = 0.03 respectively) were also found as shown in Figure 3.6 c) and
d). Higher tumor Lac:Pyr leads to a greater increase in pHi in tumoral and peritumoral
regions during glucose infusion. However, no significant correlation was found between
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tumoral or peritumoral ∆pHi with tumor SUV (ρ = -0.45, P = 0.17; ρ = -0.6, P = 0.051
respectively) as shown in Table 3.3.

Figure 3.7: The relationship between tumor Lac:Pyr vs. pHGi pre-infusion. Dotted lines
indicate the 95% confidence interval, the error bar = standard deviation

Table 3.3: Pearson’s correlation among tumor glycolysis measurements (SUV and
Lac:Pyr) and tumor and peritumor baseline pHi, pHGi and ∆pHi induced by glucose
infusion. The asterisk indicates a statistical significance of P < 0.05.
N = 11

pHit

pHip

pHGi

∆pHit

∆pHip

SUV

-0.33

-0.27

0.16

-0.45

-0.51

Lac:Pyr

-0.58*

-0.66*

0.57*

0.83*

0.76*

82

Figure 3.8: The z-spectra from the phantom experiment and the Lorentzian fitting of the
glucose peak at 2.18 ppm. The FWHM and amplitude increase as the pH increases from
6.2 to 7.4.

3.4 Discussion:
Both phantom and simulation results indicated the inversely proportional relationship
between pH and AACID values remains under normoglycemic to hyperglycemic
conditions (as shown in Figure 3.2 and 3.3), where higher AACID values are associated
with lower pH values. These results agreed with previous publications [10,11]. The results
from both the phantom experiment and simulation confirmed that the relative change of
AACID values before and after the glucose infusion captured the pHi change in vivo. The
one-way ANOVA test from the phantom measurements indicated a simple main effect of
pH on AACID values but the glucose concentration did not have a simple main effect on
the AACID values. This potentially indicates that AACID values are independent of
metabolite concentration, even in the presence of a metabolite (glucose) with a resonant
frequency close to amine. Although no simple main effect was found when evaluating
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AACID values measured with different glucose concentrations, the slopes and y-intercepts
are different when simulating three different concentrations of glucose. Because of the lack
of significant effect of glucose concentration on AACID values, we combined the data
from all phantom experiments to create an overall estimate of the slope and intercept to
relate AACID to pHi. It is worth noting that the slope and y-intercept from the current
fitting are distinct from the reported slope (-0.64) and y-intercept (6.5) without the presence
of glucose from the original AACID publication that used a FSE sequence of the same B 1
and RF duration [11]. Overall, although the glucose concentration does not have a simple
main effect on AACID, a calibration experiment with customized phantom mimicking the
experimental microenvironment would ensure the accuracy of pHi measurements using
AACID CEST MRI.
The Lorentzian fitted lines on the MTRasym spectra from the phantoms, showed an increase
in the FWHM for glucose peaks was observed as pH increased (Figure 3.8). In a previous
study, the direct proportional relationship between FWHM of MTRasym and the kex of the
corresponding metabolite was demonstrated [21]. The increasing FWHM as pH increased
from 6.2 to 7.4 confirmed the kex approximation using Equation 3.1 for simulation.
As reported from a previous publication, the baseline blood glucose of this set of rats was
7.3 mmol/L and slowly increased to > 20 mmol/L when using the same infusion protocol
on the benchtop [13]. This corresponds to brain glucose concentrations of approximately
1.8 mmol/L at baseline and > 5 mmol/L during infusion according to the estimation given
by Silver et al. [17], these glucose concentrations are comparable to the values used in the
simulation and the phantom study. The pre-infusion tumor pHi derived using the phantom
calibration is 7.17 ± 0.29, which is close to a previous study using the same tumor type and
similar time post-surgery (pHi ≈ 7.3) [6]. AACID CEST was able to capture the changes in
tumoral pHi induced by glucose infusion, with pHi in the tumor region significantly lower
during-infusion (7.03 ± 0.45) than pre-infusion. However, no significant changes of pHi in
peritumoral or contralateral brain regions were found. Decreased pHi after a glucose
infusion can be attributed to the Warburg effect, with elevated glycolytic activity, especially
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under hyperglycemic conditions, resulting in the production of excess H+ and lactate [2–4].
Peritumoral and contralateral brain cells do not rely on glycolysis as the main energy
production mechanism, possibly explaining why there was no significant change in the pH
environment during glucose infusion. The peritumoral pHi before and during glucose
infusion was significantly lower than tumoral pHi – this may also be a result of aberrant
tumor metabolism. As mentioned above, surplus acid is produced because of tumor
glycolytic metabolism. Excess acid would travel through the pH gradient to neighboring
cells to avoid acidosis which could lead to cell death [2]. In combination with poor tumor
perfusion environment explored in previous studies [13-15], all of these factors would lead
to a significantly lower peritumoral pHi. This pH gradient could also be an indication of
tumor invasion to the peritumoral region [1,3,22].
Studies have found that the tumor extracellular (pHe) environment becomes more acidic
towards the tumor edge and the peritumoral regions, this is the result of the elevated
activation of glucose transporters and poor tumor perfusion [2,3,13-15]. This study
indicates a similar pHi distribution as the peritumoral pHi is significantly lower than the
tumor pHi. The significant correlation between tumor Lac:Pyr and baseline
tumor/peritumor pHi emphasizes the effect of tumor anerobic glycolysis on its pH
environment. Higher tumor glycolytic activity has been associated with lower extracellular
pH (pHe) [2,6,9,22,23]. In this study, higher tumor anerobic glycolytic activity is linked
with lower tumoral and peritumoral pHi. A significant correlation was also found between
tumor Lac:Pyr and the pHi gradient from the tumor to peritumor region, with higher
Lac:Pyr corresponding to a higher pHGi. The conversion of pyruvate to lactate during
anerobic glycolysis, as measured with hyperpolarized [1-

13

C]pyruvate (Lac:Pyr), more

directly captures the process of tumor acidosis, and indicated a directly proportional and
significant relationship with the pHGi across the tumor to peritumor region.
Although all imaging experiments were performed in 24 hours, they were in the span of
two days, specifically, FDG-PET on Day 11-13, and CEST followed by the hyperpolarized
[1-13C]pyruvate on the next day. Although this is a practical limitation, all imaging was

85

completed within 24 hours for each subject and no significant changes were found in tumor
volumes as mentioned in our previous publication [13]. Since tumor pH and the glycemic
environment were not identical between these measurement sessions, this could explain
the absence of significant correlations between tumor SUV from FDG-PET and tumoral
and peritumoral pHi. The tumor pH environment measured from CEST would be closer to
the hyperpolarized pyruvate experiment than during FDG-PET, acquired a day prior. The
sequential design of the study also gave rise to distinct glucose conditions prior to the
glycolysis measurements. The subjects were normoglycemic before FDG-PET while they
were hyperglycemic prior to hyperpolarized [1-13C]pyruvate experiment as it was
conducted the following day immediately after the dynamic CEST experiment. Under the
effect of hyperglycemia, directly proportional relationships were found between tumor
Lac:Pyr vs. tumor and peritumor ∆pHi. A higher tumor Lac: Pyr is related to a greater shift
towards the basic direction in tumor and peritumor pHi. This could be because cells in
tumoral and peritumoral regions try to maintain pH homeostasis to avoid acidosis which
results in cell death [1,2].
In summary, the relationship between tumor intracellular pH environment and tumor
glycolysis was examined in this study. Significant inversely proportional relationships
between tumor and peritumor pHi and tumor Lac:Pyr were found; as well as significant
directly proportional relationships between tumor and peritumor ∆pHi and tumor Lac:Pyr.
There were several limitations from this study, to follow the radiation safety protocols at
different sites, the rats had to be housed at our PET facility overnight before they could be
transferred to the MR facility. In the future, experiments could be carried out on a hybrid
PET/MR system not only to simplify the experimental procedure but also to provide
simultaneous measurements under the same tumor pH and metabolic microenvironment.
The precise roles of glucose transporters were not examined in this study – histological
information about these transporters will be acquired in future studies, and the correlation
between the distribution of these glucose transporters and the tumor pHi environment can
then be evaluated [2,3]. A measurement of pHe would also aid in interpreting these results.
We plan on acquiring this information in a future study simultaneously with acidoCEST
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[7,9] to provide a more complete picture of the tumor pH environment. The current 60-min
glucose infusion protocol leads to hyperglycemia by the end of the AACID CEST
experiment. The acute change in pHi environment after the glucose infusion was not
measured in the current study since a different CEST acquisition protocol was used during
the first half of glucose infusion. Moreover, the Lac:Pyr value obtained from the MRSI
right after would be elevated under hyperglycemia [13,24,25] – a CEST acquisition
promptly following a bolus injection with a moderate dose of glucose will be implemented
in the future to avoid an overly large alteration of the tumor glycolytic environment.

3.5 Conclusions:
This study demonstrated that using AACID CEST MRI, a change in tumor pHi can be
detected after glucose infusion, the presence of metabolites with similar resonant
frequencies with amine or amide would not significantly affect AACID although the
calibrations were distinct under different metabolite concentrations. Tracking changes in
tumor pH could provide information about tumor metabolism and pH imaging using
AACID CEST MRI can be used as an alternative for tumor metabolic imaging.
Hyperglycemia induced by glucose infusion leads to a change in tumoral pHi that can be
detected in vivo using CEST MRI. The relationship between tumor and peritumor pHi
environment and tumor glycolysis were explored. Tumor Lac:Pyr is significantly inversely
proportional to tumor and peritumoral pHi, it is also significantly directly proportion to
tumoral and peritumoral ∆pHi induced by a glucose infusion. The associations emphasize
the innate relationship between tumor glycolytic metabolism and the tumor pH
environment as well as the peritumor pH environment. A multimodal imaging approach
could provide a more complete picture of the process of tumor progression and invasion
by monitoring both tumor glycolysis and the change in the pH environment.
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Chapter 4
Evaluation of the Change in Tumor Intra-/Extracellular
pH Environment Induced by Glucose Injection and its
Relationship with Tumor Glycolysis in a C6 Rat Model
of Glioblastoma
Qi Qi, Matthew S. Fox, Heeseung Lim, Rebecca Sullivan, Harris Smailovic, Alex Li,
Miranda Bellyou, Lise Desjardins, Andrew McClennan, Robert Bartha, Lisa Hoffman,
Timothy J. Scholl, Ting-Yim Lee, Jonathan D. Thiessen
In the previous chapter, we explored the relationship between tumor glycolysis and its
intracellular pH environment, but the information regarding extracellular pH in the tumor
was missing. In this chapter, we investigated tumor glycolysis along with both intra- and
extracellular pH. One of the hallmarks of glioblastoma is the reliance on glycolytic
metabolism, even with adequate oxygen supply. Excess acid and H+ are produced from
glycolysis, resulting in a more acidic tumor environment. Consequently, a glucose injection
could lead to a drop in tumor pH. Chemical exchange saturation transfer (CEST) MRI can
be used in vivo to detect intracellular pH (pHi) with amine and amide concentration
independent detection (AACID) as mentioned in previous chapter, and extracellular pH
(pHe) with acidoCEST using iopamidol. Glucose metabolism can be evaluated using
kinetic modeling of dynamic positron emission tomography (PET) data obtained from 18Ffluorodeoxyglucose (FDG). In this chapter, we compared CEST measurements of AACID
and acidoCEST to FDG-PET to explore the relationship between the tumor pH
environment and glycolytic metabolism. We demonstrate the capability of simultaneous
measurements of pHi and pHe using CEST MRI and provided a more complete picture of
tumor pH environment. Metabolic rate of glucose (MRGlu) was used to demonstrate the
intrinsic relationship between tumor glycolysis and tumor pHe.
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4.1 Introduction
Aerobic glycolysis is used as a primary energy production method for cancer cells, in
contrast with normal mammalian cells, that rely on more efficient oxidative
phosphorylation as the main means for energy production. Due to the overreliance on
aerobic glycolysis (Warburg effect), excess H+ and lactatic acids are produced as a
byproduct, and the amount produced is directly proportional to the level of glycolytic
activity [1–3]. In order to avoid intracellular acidosis, cancer cells are innately equipped
with a number of proton or acid transporters such as monocarboxylate transporters (MCTs)
to help transfer these acids to the extracellular space. When compared to normal
mammalian cells, a slightly more alkaline intracellular pH (pHi) in combination with a
more acidic extracellular pH (pHe) are the result of cancer cell pH regulation. This pH
distribution is regarded as a hallmark of malignant cancers and the pH gradient across intraand extracellular space is found to be associated with low survival outcome [4]. The acidic
pHe has also been found to benefit cancer proliferation, as it can promote cancer cell
invasion, metastasis and decrease the effectiveness of conventional cancer treatments [2,3].
In order to reverse the detrimental outcome due to the cancer pH profile, chemotherapy
agents have been designed to neutralize the acidic pHe or acidify the pHi [3]. It is important
to monitor these processes in vivo to track if treatment outcome is achieved.
Chemical exchange saturation transfer (CEST), a magnetic resonance imaging (MRI)
technique, enables the surveillance of pH changes in vivo [5,6]. Amine and amide
concentration independent detection (AACID) is sensitive to pHi. It is based on distinct,
pH-mediated proton exchange behaviors between intracellular amine (2.75 ppm) and
amide (3.5 ppm) metabolites with the intracellular water pool [7,8]. Another CEST
technique, acidoCEST, is sensitive to pHe. It relies on an exogenous contrast agent,
iopamidol, which only occupies the extracellular space. Similar to AACID, protons in two
distinct amide groups on iopamidol have pH-mediated exchange properties that can be
measured using CEST [9,10]. These two CEST methods rely on metabolite resonant
frequencies with sufficient separation to enable simultaneous measurements of pHi and
pHe.
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Aerobic glycolysis can be monitored with positron emission tomography (PET) using 18Fflurodeoxyglucose (FDG). FDG is a glucose analogue often used to evaluate cancer
glycolytic metabolism. FDG pharmacokinetics can be represented by an irreversible, twotissue compartment model, simplified by using a Patlak graphical analysis method [11].
The metabolic rate of glucose (MRGlu) can be derived from the kinetic analysis to provide
an accurate evaluation of aerobic glycolysis [12].
In this study, the intrinsic relationship between tumor glycolytic metabolism and tumor pH
environments (pHi and pHe) are evaluated. To monitor acute alteration of intra- and
extracellular tumor pH environments simultaneously using CEST, a glucose injection was
used to induce a change in pH.

4.2 Methods:
4.2.1 Experiment Design
All procedures were performed in compliance with the Canadian Council for Animal Care.
C6 glioma tumor cells were implanted using stereotactic surgery on Day 0 followed by an
MRI tumor check on Day 7 to see if the longest diameter of the tumor had reached 4 mm
[13–15]. The FDG-PET experiment was performed on Day 11. The animals were kept in
the PET facility overnight for radiation decay before being transported to the 9.4 T MR
facility for the CEST experiment on the following day (Day 12). Subjects were euthanized
immediately after the CEST experiment, and the brain tissues were extracted, fixed and
stained using hematoxylin and eosin (H&E). Experimental timeline and the detailed CEST
experiment design are shown in Figure 4.1.

4.2.2 C6 cell implantation
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Male Wistar rats (Charles River, Canada, age 8 to 10 weeks at surgery) weighing on
average 301.5 ± 22 g (N = 11) were used in this study. The animals were induced with 5%
isoflurane and were maintained at 2-3% for all surgical and imaging procedures.
Detailed C6 glioma cell culturing and implantation can be found in a previous publication
[13,15]. In short, 1 million C6 glioma cells were injected 3–4 mm from the skull surface at
a burr hole 1 mm anterior and 3 mm right of the bregma and with a Hamilton syringe with
the aid of a stereotactic frame. The burr hole was sealed with bone wax, and the incision

Figure 4.1: a) Study overview, Day 0 denotes the day of C6 glioma cell implantation.
An MR tumor check took place on Day 7. The FDG-PET experiment was carried out
on Day 11, with follow up CEST experiment on the morning of the next day (within 24
hours). b) Simultaneous AACID and acidoCEST experimental design. A bolus (0.05 ml)
followed by the start of a constant infusion (3.3 gI/kg over 44 minutes) of 300 mgI/ml
of Iopamidol took place prior to the start of the CEST acquisition. A baseline CEST
acquisition took place before the bolus injection of 20% D-glucose (0.3 g/kg), followed
by another post-injection CEST acquisition.
was closed with sutures. The subjects were recovered and returned to the animal care
facility.
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4.2.3 Benchtop blood glucose measurement
Dynamic blood glucose changes were measured by sampling blood from a rat tail artery
(weight = 510 g) and measuring blood glucose with a glucometer (Contour 7152B, Bayer
HealthCare, Leverkusen, Germany) on the benchtop using the same glucose injection
protocol used during the CEST experiments. The baseline blood glucose was measured
before the injection of a bolus of 20% glucose-saline solution (0.3 g/kg of the rats). The
blood glucose of the subject was measured approximately every 5 minutes after the start of
glucose infusion for 40 minutes.

4.2.4 MR tumor check
Subjects were imaged on Day 7 using a 3T MRI (Siemens Biograph mMR) with a
transmit/receive quadrature rat brain RF coil (Cubresa, 44 mm inner diameter). A turbo
spin echo (TSE) sequence (128 x 128 field-of-view, FOV; 0.2-mm in-plane resolution; 3mm slice thickness; slice number = 10; repetition time, TR = 4710 ms; echo time, TE =
100 ms; 10 echo trains and 4 averages) was used to acquire axial T2-weighted MRI. A line
of the longest diameter was drawn on the tumor to confirm it was longer than 4 mm [13,16].

4.2.5 FDG-PET
The FDG-PET acquisition took place on Day 11 using a small animal PET system (Inveon
DPET, Siemens Healthineers, Knoxville, TN, USA). The blood glucose level of each
subject was tested using the same glucometer prior to FDG-PET acquisition. A 90-minute
emission scan was performed with a timing window of 3.432 ns and 350-640 keV
discrimination energy range. Approximately 30 s after the acquisition had started, a bolus
of 18F-FDG (34.3 ± 4.8 MBq) was injected through a lateral tail vein.
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Longitudinal PET data were histogrammed into 53 successive time intervals comprised of
1 frame of 30 s, 20 frames of 3 seconds, 7 frames of 30 seconds, 10 frames of 60 seconds
and 15 frames of 300 seconds, totaling 90 minutes. An iterative, 3D ordered subset
expectation maximization (OSEM3D) reconstruction was used to generate dynamic images
for all frames with 2 iterations and 18 subsets.

4.2.6 CEST experiment
MRI was acquired on a 9.4-T small animal MRI (Bruker Corporation, Billerica,
Massachusetts, USA) the day after PET on Day 12. Axial T2-weighted images using a 2dimensional fast spin-echo (FSE) sequence (TR = 3000 ms; TE = 10 ms; effective TE = 40
ms; echo train length = 4; number of slices = 29; slice thickness = 1 mm; FOV = 3.84 × 3.84
cm; matrix size = 128 × 128; acquisition time = 179 s) were acquired first to locate the slice
that contained the largest tumor cross-section axially.
CEST spectra were acquired using a continuous echo planar imaging (EPI) sequence, with
a series of EPI images acquired on the same axial slice localized using the FSE sequence.
The parameters for the EPI sequence are saturation time (TS) = 5 s; B1 = 3 μT; offset
frequency pulse alternated between negative and positive, from -6/+6 to 0 ppm with 0.2
ppm steps; TR = 10 s; effective TE = 25 ms; echo train length = 48; slice thickness = 2
mm; FOV = 3.84 x 3.84 cm FOV; matrix size = 96 × 96, number of averages = 2,
acquisition time = 22 min. Two spectra were obtained from two consecutive 22 min CEST
acquisitions. A bolus of 300 mgI/ml of iopamidol (0.05 ml, Isovue, Bracco Diagnostics
Inc, Vaughan, Canada) was injected prior to the first CEST acquisition, along with a 44min constant infusion of the same concentration of iopamidol at a dose of 3.3 gI/kg. The
first CEST spectrum (Baseline) was acquired prior to the glucose injection. A bolus of 20%
D-glucose solution (0.3 g/kg, Sigma Aldrich, Miamisburg OH, USA) was injected at the
end of the first spectrum acquisition. The acquisition of the second (Post-injection) CEST
spectra took place after the glucose injection.
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The post injection CEST spectrum was used to compare with the baseline CEST spectrum
to examine the effect of glucose infusion on pHi and pHe.

4.2.7 Kinetic analysis of FDG-PET
PET kinetic analysis was performed using PMOD 3.9 (PMOD Technologies LLC, Zürich,
Switzerland). An arterial input function (AIF) was defined using the averaged time-activity
curve (TAC) from an ROI drawn covering the left ventricle. The equation for the Patlak
plot is shown in Equation 4.1. The whole brain including the tumor region was delineated
and the pixel-wise TACs were normalized by the input function and plotted against the
ratio of the integral of the input function and input function (Patlak graphical analysis,
[11]).
TAC(t)
AIF(t)

T

= Ki ×

∫0 AIF(t)
AIF(t)

+ Int

[4.1]

Where Int is the y-axis intercept and the slope of the linear portion, representing the net
transfer rate (Ki), was obtained and converted into MRGlu using Equation 4.2.
MRGlu = K i ×

CGlucose Plasma
LC

[4.2]

Where CGlucose Plasma is the plasma glucose concentration measured prior to FDG
injection, and LC is the lumped constant, a conversion factor to estimate the glucose
metabolic rate from the glucose analog FDG. LC = 0.71 was used based on literature
[17,18].

4.2.8 acidoCEST phantom calibration
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In order to test the effect of glucose on acidoCEST, two pH phantoms were made using
modified recipes from published works [9,10]. One phantom was used as a control (i.e.,
without glucose), it holds seven NMR tubes (Sigma Aldrich, Miamisburg OH, USA), and
each tube contains a mixture of 1 × phosphate buffered saline (PBS, pH = 7) and the same
concentration of iopamidol (30 mM). pH of the solution in each tube was titrated by either
adding sodium hydroxide (NaOH) or hydrogen chloride (HCl) to obtain seven pH levels
from 6.2 to 7.4 with 0.2 increments. The second phantom was made with the same pH
levels with the addition of 6 mM glucose to mimic brain tissue glucose levels under
hyperglycemia [19].
As shown in Equation 4.3, the magnetization transfer ratio asymmetry (MTRasym, [5,6])
was calculated at the resonant frequencies of the exchangeable protons of the two amide
functional groups in iopamidol (4.2 and 5.5 ppm).
MTR asym =

S−∆ω − S∆ω
S0

[4.3]

pH vs. the corresponding MTRasym values at the two resonant frequencies with (Figure
4.2a) and without glucose (Figure 4.2b) were plotted. The ratios of the MTRasym signals at
the resonant frequencies (4.6 and 5.5 ppm) of the two amide functional groups on
iopamidol were calculated (Equation 4.4).
R ST =

MTRasym (4.2 ppm)
MTRasym (5.5 ppm)

[4.4]

The relationship between RST and the corresponding pH was plotted in Figure 4.2c. An
exponential function was fitted and plotted, and the goodness-of-fit was tested. The
equation was then used to convert the ratio obtained from in vivo CEST experiments to pH.
The area under the curve (AUC) was also calculated using MTRasym (AUCMTR) values
from 1.2 to 2.8 ppm to generate regional glucose maps [15].
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Figure 4.2: pH vs. MTRasym values at the resonant frequencies of the exchange protons
on the two amide functional groups on iopamidol without a. and with b. the presence of
glucose (6 mM). c. pH vs. the corresponding RST value calculated using acidoCEST
measurements obtained from the phantom experiments. Error bar = standard deviation.

4.2.9 Tumoral and pertitumoral pHi, pHe and pH gradient
AACID values were calculated from the Z-spectra using Equation 4.5 for both baseline
and post-injection CEST acquisitions. Calculated AACID values were converted using the
same calibration as indicated in Equation 4.6 from a previous study (Chapter 2, [15]). The
ratio (RST) obtained from acidoCEST was converted to pHe using an exponential
calibration derived from the phantom experiment described above. pH gradient (pHG)
across the intra- to extracellular space was calculated as shown in Equation 4.7.
Mz(3.50 ppm) × (Mz(6 ppm) − Mz(2.75 ppm) )

AACID = Mz

(2.75 ppm) × (Mz(6 ppm)

− Mz(3.50 ppm) )

AACID = −0.45 × pH𝑖 + 4.88
pHG = pHi − pHe

4.2.10 Histology

[4.6]
[4.7]

[4.5]
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Animals were euthanized with an overdose of potassium chloride immediately after the
end of CEST experiment. The animals were perfusion-fixed with phosphate buffered saline
followed by 4% paraformaldehyde. Brains were removed and fixed in 4%
paraformaldehyde for 24 hours. Brain specimens were sectioned into 3 mm thick blocks,
paraffin-embedded, sectioned at 5 μm in the axial orientation picked up on positively
charged microscope slides and dried overnight at 37°C. The brain sections were
deparaffinized in xylene, hydrated through graded alcohols and washed in water. The slides
were then placed in a bath of 3% H2O2 for 10 minutes to block peroxidase activity, washed
in running tap water for 5 minutes, rinsed in distilled water and placed in pH 7.4 PBS. The
slides were incubated 40 minutes at room temperature. The slides were then washed 3 x 5
minutes with PBS before DAB (3,3’-diamiobenzidine, Vector Laboratories, Inc.) was
applied for 8 minutes. The slides were subsequently washed in running tap water,
counterstained with Carazzi’s haematoxylin for 1 minute, washed with tap water,
dehydrated through graded alcohols, cleared in xylene and mounted.
The brain slides were imaged and captured using a digital bright-field microscope (Zeiss
Axioscope, Oberkochen, Germany).

4.2.11 Image registration and ROI selection
Detailed description can be found in a previous publication (Chapter 2, [15]). T2-weighted
MRI was used as guidance for manual delineation of tumor, peritumor and contralateral
brain regions as well as a reference for coregistration of CEST MRI, FDG-PET and
histology images using 3D Slicer (www.slicer.org). The average tumoral, peritumoral and
contralateral brain pHi, ∆pHi, pHe, ∆pHe and pHG from CEST, along with MRGlu from
FDG-PET, were extracted. Illustrative examples of co-registered CEST, PET and
histology, and the delineations of the three different regions are shown in Figure 4.3 and
Figure 4.4.
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Figure 4.3: Illustrative example of all registered images and ROIs for one rat. T2weighted MRI acquired on the 9.4 T MRI is used as a reference to co-register CEST
MRI (a, b, e and f), FDG-PET (c and g) and the corresponding H&E images with
different magnifications (d and h). The tumor, peritumor and contralateral brain regions
are delineated using the T2-weighted MRI with the red-, beige- and blue-dotted lines
respectively.

Figure 4.4: Illustrative example of all registered images and ROIs for another rat, T2weighted MRI acquired on the 9.4 T MRI is used as a reference to co-register CEST
MRI (a, b, e, f and g), FDG-PET (c and d) and the corresponding H&E image (h). The
tumor, peritumor and contralateral brain regions are delineated using the T2-weighted
MRI with the red-, beige- and blue-dotted lines respectively. The red arrows indicate a
potential co-localization of tumor necrosis between CEST MRI and histology.
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4.2.12 Statistical analysis
A two-tailed paired T-test was performed to determine if significant differences (P < 0.05)
can be found in tumoral and peritumoral pH after a bolus injection of glucose solution.
Pearson’s correlation test was used to investigate the relationship between tumor glycolytic
measurement of MRGlu with tumoral and peritumoral pH environment measurements
(pHi, pHe and pHG) as well as glucose distribution (AUCMTR). A P-value less than 0.05
was defined as a significant correlation.

4.3 Results:
4.3.1 Blood glucose measurement
Benchtop measurements of blood glucose as a function of time during the glucose infusion
protocol are plotted in Figure 4.5. The baseline blood glucose of the subject was 6.9
mmol/L and increased to 15.3 mmol/L 15 minutes after the bolus injection of glucose, the
blood glucose later dropped to 9.3 mmol/L 30 minutes after the injection (i.e., end of the
injection protocol).
During the in vivo CEST experiment, the average blood glucose level at baseline was 7.2
± 2.3 mM, and the average blood glucose level post-injection was significantly higher, at
15.6 ± 5.5 mM.

4.3.2 Calibration of acidoCEST to pHe
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Figure 4.5: An illustrative example of blood glucose changes 30 minutes after an injection of a
bolus of 20% glucose solution (0.3 g/kg).
After examining the relationship between pHe vs. RST from the two phantoms (with and
without glucose), no significant differences were found in RST values at each pHe value
regardless of the presence of glucose (Figure 4.2).
The equation of between pHe and RST obtained from the line-of-best-fit indicated by an
exponential function was:

RST = 0.0032 × e0.837 × pH
and the goodness-of-fit (R2) was 0.95.

4.3.3 The effect of glucose injection on pHi and pHe
Baseline and post-injection averaged pHi and pHe in tumor, peritumor and contralateral
brain tissue are illustrated in Figure 4.6. After the glucose injection, a significant decrease
in pHi was found in tumor (P = 0.02) and peritumor (P = 0.01) regions but not in the
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contralateral brain region (P = 0.12). A significant decrease in pHe was found in tumor (P
< 0.01), peritumor (P < 0.001) and contralateral brain tissue (P = 0.03) regions.
At baseline, tumor pHi was significantly higher than pHi in peritumor (P < 0.01) and
contralateral brain regions (P = 0.04), and tumor pHe was significantly lower than pHe in
peritumor (P = 0.03) and contralateral brain (P = 0.02) regions; peritumor pHe was
significantly lower than contralateral brain pHe (P = 0.01).
After glucose injection, pHi in tumor and peritumor regions were significantly lower than
pHi in the contralateral brain region (P = 0.03 and P < 0.001 respectively), tumor pHi was
significantly higher than the peritumor region (P = 0.02); tumor and peritumor pHe were
both significantly lower than contralateral brain pHe (P < 0.01 and P = 0.01 respectively).

Figure 4.6: Mean pH values of all rats (N = 11) from ROIs defined in tumor, peritumor
and contralateral brain tissue in pHi (a) and pHe (b) at baseline and post-injection. Error
bar = standard deviation.

4.3.4 Kinetic analysis results
The averaged MRGlu values in the tumor, peritumor and contralateral brain regions are
illustrated in Figure 4.7, MRGlu in tumor region is significantly higher than peritumor (P
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< 0.001) and contralateral brain (P < 0.001) MRGlu. MRGlu in the peritumor region is not
significantly different from the contralateral brain region (P = 0.67).

Figure 4.7: Mean MRGlu measurement in the tumor, peritumor and contralateral brain
regions. The error bar = standard deviation.

4.3.5

Correlation

between

tumoral,

peritumoral

pH

measurement and tumor glycolysis
As shown in Table 4.1, significant correlations were found between baseline tumor
glycolytic measurement of MRGlu and tumor pHi (ρ = 0.78, P = 0.03) (Figure 4.8a), tumor
pHe (ρ = -0.87, P < 0.001) (Figure 4.8b), as well as the tumor pHG (ρ = 0.70, P = 0.012).
Table 4.1: Pearson’s correlation among baseline tumor glycolysis measurements
(MRGlu), tumor and peritumor pH environments (pHi, pHe and pHG) and AUCMTR. The
asterisk indicates a statistical significance of P < 0.05.
N = 11

pHit

pHip

pHet

pHep

pHG

AUCMTR

MRGlu

0.78*

0.56

-0.87*

-0.47

0.70*

0.14
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As shown in Table 4.2, tumor and peritumor ΔpHi are significantly correlated (ρ = 0.81, P
< 0.001), the tumor and peritumor ΔpHe are also significantly correlated (ρ = 0.81, P <
0.001). Tumor MRGlu is inversely proportional and significantly correlated with ΔpHe in
the tumor region (ρ = -0.83, P = 0.02) (Figure 4.8c). Tumor ΔpHi is inversely proportional
and significantly correlated with peritumor ΔpHe (ρ = -0.65, P = 0.02) (Figure 4.8d).

Figure 4.8: Tumor glycolytic measurement of MRGlu vs. tumor pHi a, tumor pHe b,
tumor ∆pHe c, and tumor ∆pHi vs. peritumor ∆pHe d. The dotted line indicates the 95%
confidence interval, and the error bar denotes the standard deviation.
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4.3.6 Histological validation
The H&E staining indicated the location of tumor highlighted by the red arrows as shown
in Figure 4.3d, the zoomed-in tumor region is shown in Figure 4.3h. A potential colocalization of necrosis between CEST MRI and histology is indicated by the arrows in
Figure 4.4g and 4.4h.

Table 4.2: Pearson’s correlation among tumor glycolysis measurement (MRGlu) and
tumor and peritumor ∆pH (∆pHi and ∆pHe) induced by glucose injection. The asterisk
indicates a statistical significance of P < 0.05.

∆pHit

∆pHip

N = 11

MRGlu

∆pHit

0.45

∆pHip

0.28

0.81*

∆pHet

-0.83*

-0.04

0.13

∆pHep

0.26

-0.65*

0.53

∆pHet

0.78*

4.4 Discussion
In this study, the association between glycolysis and tumor pH environment was
investigated in vivo in the C6 rat model using FDG-PET and CEST. All imaging
experiments were performed within 24 hours and the tumor size should not change
significantly within a 24-hour span according to our study presented in Chapter 2 [15].
From the phantom experiment, the addition of glucose solution did not affect the RST values
at different pH, as the RST values derived from the phantom containing glucose (with a
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concentration of 6 mM) were not significantly different from the phantom without glucose
across a range of physiologically-relevant pH values. As a result, the RST values from both
phantoms were used, and the exponential relationship between pHe and RST was
determined. The equation used to calibrate in vivo RST to pHe produced in vivo tumor
extracellular pH levels (average 6.53 ± 0.11, mean ± standard deviation) similar to the pHe
level obtained from Chen et al. (~6.5, [9]), Lim et al. (7.19 ± 0.11 [4]), Volk et al. (6.796.85, [19]) and Longo et al. (6.5-7.1, [10]).
At baseline, the average tumor pHi measured using AACID is 7.29 ± 0.12, higher than pHi
in the peritumor and contralateral brain regions. Meanwhile, the average tumor pHe
measured using acidoCEST was lower than in peritumor and contralateral brain regions.
This was a likely result of the Warburg effect, with an alkaline pHi in combination with a
more acidic pHe aiding in tumor proliferation [1,2,4]. The average tumor pHi obtained from
this study (7.29 ± 0.10) was very similar to a previous study by Lim et al. (7.30 ± 0.09,
[4]). This indicates that the calibrations used from this study could produce acceptable
results. Importantly, we were able to measure intra- and extracellular pH simultaneously
during this study, with the presence of a glucose solution in the system having no apparent
effect on our pHi estimates. The resonant frequencies needed for acidoCEST are further
away from glucose, amine and amide resonant frequencies, as a result, no significant
difference was found for RST values with and without glucose at various pH as shown in
the phantom result.
After glucose injection, significant decreases in intra- and extracellular pH in both tumor
and peritumor regions were detected using AACID and acidoCEST simultaneously. The
injected glucose was utilized in tumor glycolysis and led to an acute decrease in tumor and
peritumor pH environment (pHi and pHe) as more H+ and acid were produced through
glycolysis. A drop of 0.3-0.4 in pHe was found across various cancer types after an
intravenous infusion of glucose solution. by Volk et al. [19]; meanwhile, a drop of 0.72 in
pHi was observed by Albatany et al. [20] after an intraperitoneal glucose injection. The
results from this study illustrated a similar decrease in pHi and pHe (a decrease of 0.41 ±
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0.1 and 0.30 ± 0.07 respectively) with a bolus injection of glucose. The excess H+ and acid
produced by the tumor cells due to glucose injection could accumulate in the peritumor
regions as the upregulation H+ and acid transporters especially at the edge of the tumor [1–
3], in turn these H+ and acid are transferred to the peritumor region and alter the pH
environment in these regions. This could indicate the process of tumor invasion, as acidosis
led apoptosis in peritumor regions results in the breakdown of the extracellular matrix and
help tumors spread into these areas [1,2]. The possibility of detecting a pH environment
change induced by a glucose injection could be valuable to observe other pH alteration
procedures in cancer treatment to monitor treatment outcomes.
The tumor MRGlu was significantly greater than peritumor and contralateral brain tissue,
further highlighting the Warburg effect, with higher glycolytic metabolism in tumor
compared to contralateral brain tissue as well as peritumor tissue. Although the peritumor
region could potentially be a site of tumor invasion, the rate of glycolysis was not
significantly higher when compared to contralateral brain tissue.
The tumor MRGlu derived from FDG-PET kinetic analysis was significantly correlated
with the tumor baseline pHi, pHe and pHG. Greater tumor MRGlu is associated with higher
tumor pHi, lower tumor pHe and a higher pHG. This matches what we would expect to see
in tumors with higher glycolytic activity, leading to a more acidic pHe and a greater pHG
across the intra- and extracellular space. pHG has been found to be associated with tumor
proliferation [4], more alkaline or higher pH values are associated with higher tumor
mitotic activity [4] which is a hallmark of glioblastoma [21,22], and this study has provided
additional information on the association with tumor metabolism and growth. This further
highlights the intrinsic relationship between the Warburg effect in the tumor and its pH
environment.
Tumor ΔpHi and ΔpHe are significantly correlated with peritumor ΔpHi and ΔpHe
respectively. Tumor and peritumor pH environments changed concurrently when induced
by the glucose injection. This might indicate the innate relationship between the tumor and
peritumor pH environment, as well as the effect of tumor glycolytic activity on the pH
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environments. Significant correlation was found between tumor MRGlu and tumor ΔpHe,
showing that higher tumor glycolytic activity is associated with a greater decrease in tumor
pHe. The injection of glucose will lead to elevated production of H+ and acid in the tumor
based on the tumor glycolytic activity, and they will be transported to the extracellular
space and lead to a greater drop in pHe. An inversely proportional and significant
relationship was found between tumor ΔpHi and peritumor ΔpHe, with an increase in tumor
ΔpHi linked to a decrease in peritumor ΔpHe. Under elevated glucose conditions, as more
H+ and acid are produced, tumor cells will transport these H+ and acid out of the cells to
avoid acidosis. As a result, H+ and acid accumulate not only in the tumor extracellular
space but could also spill over into the peritumor extracellular space [1,23].
Although significant correlation was not found between tumor AUCMTR and FDG-PET
measurements from this and previous studies [15], a good colocalization of high intensity
regions within the tumor can be seen among AUCMTR and FDG-PET measurements as
shown in Figure 4.3. From Chapter 2 [15], the low intensity values of AUCMTR within the
tumor region was hypothesized to be possible tumor necrosis. In this study, a potential
colocalization of tumor necrosis is observed between AUCMTR map and the corresponding
histology slide highlighted by the red arrows as shown in Figure 4.3. Using CEST
measurements of AUCMTR in addition to the pH measurements, the tumor metabolic
activity could be estimated.
There are a couple of limitations for this study: the CEST acquisition did not take place
right after the PET experiment to follow the radiation safety protocol at different sites. The
subjects have to be housed at the PET facility overnight for radiation decay before
transferring to the 9.4 T MR facility for imaging, however, the imaging experiments for
each subject were performed within a 24-hour span. A hybrid PET/MR system could be
used in the future to provide simultaneous measurements under the same tumor
microenvironment. The role of glucose transporters is not studied in this study, other
studies have demonstrated the inversely proportional relationship between the number of
glucose transporters and tumor and peritumor pHe (more acidic) [1,24]. The Patlak
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graphical analysis method assumes the pharmacokinetics of FDG are irreversible [25], i.e.
FDG6P will be trapped inside the cells after FDG is phosphorylated. However, a recent
study has shown the reversibility of FDG6P trapping, where FDG6P could be fed into
pentose phosphate pathway by glucose-6-phosphate dehydrogenase, and in turn be
transported out of the cell by GLUTs [26]. A Logan graphic analysis method could be
employed to better model FDG pharmacokinetic, as it assumes reversible binding for
radiopharmaceuticals [11].

4.6 Conclusion
To our knowledge, this is the first study that demonstrated the possibility of measuring
both intracellular and extracellular pH simultaneously using CEST MRI and demonstrated
the capability of measuring the tumor intra- and extracellular pH environments, as well as
detecting the change in pH after a glucose injection. The intrinsic relationship between
tumor and peritumor pH environments (tumor pHi and peritumor pHe) could potentially
help predict tumor invasion. Tumor glycolytic metabolism and its effect on tumor pHe was
also shown in this study, and further illustrates the importance of understanding the tumor
pH environment as it relates to tumor metabolism.
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Chapter 5
Discussion and Future Direction
The aim of this thesis is to investigate cancer perfusion, metabolic and pH environment
using CEST MRI along with multimodal imaging approach. Conclusion and limitations of
each chapter is discussed below.

5.1 Chapter 2: Multimodality In Vivo Imaging of Perfusion and Glycolysis in a
Rat Model of C6 Glioma
In this chapter, the association between tumor perfusion and tumor glycolysis was
investigated in vivo using CTP, FDG-PET and hyperpolarized [1-13C]pyruvate MRSI in a
C6 rat model of glioma. Dynamic glucose enhancement measurements of tumor ΔCEST
were significantly correlated with tumor perfusion measurements of BV and PS but not
tumor glycolysis measurements of SUV and Lac:Pyr, suggesting that glucose CEST
imaging using ΔCEST functions primarily as a perfusion tracer. Conversely, tumor
glycolysis measurements of SUV and Lac:Pyr were significantly correlated with perfusion
measurements of PS, reflecting increased tumor leakiness in tumors with higher glycolytic
metabolism. Moreover, tumor perfusion measurement of BF and BV were significantly
corelated with tumor SUV and Lac:Pyr respectively, this further emphasize that better
perfusion environment could result in better glucose delivery to cancer cells and can later
be used in cancer glycolytic metabolism.
The ROI defined using the T2-weighted MRI will contain CSF, and the inclusion of CSF
in tumor ROIs could lead to underestimation of all measurements in the tumor regions as
CSF is distinct from the contrast agent in the blood vessels and tissue. Although the
imaging measurements were conducted within 24 h, they were in the span of 2 days, and
on multiple scanners, as a result, the tumor perfusion and glycemic environment were not
identical during the measurements. CEST measurements of the immediate response during
glucose infusion were missing because CEST experiments for the first 30 min of the
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glucose infusion were performed with two different protocols. Confounding these results
is the fact that hyperglycemia induced by a constant infusion of glucose during dynamic
CEST experiments may lead to a more acidic pH environment and give rise to
underestimation of CEST measurements. Subsequently, in approximately half of the
dynamic glucose CEST experiments, there was a drop in CEST signal post-glucose
infusion. Although glucose CEST measurements may yield additional novel information
about tumor status, the complicated dependency of glucose CEST signal on a variety of
factors would benefit from additional in vivo mechanistic studies.

5.2 Chapter 3:

Glucose Infusion Induced Change in Intracellular pH and Its
Relationship with Tumor Glycolysis in a C6 Rat Model of Glioblastoma.

In this chapter, the tumor pHi environment was evaluated using AACID CEST MRI, and
AACID CEST MRI was tested to detect the change in pHi environment induced by a
glucose infusion. The relationship between tumor pHi environment and its glycolytic
activity measured using FDG-PET and hyperpolarized [1-13C]pyruvate was also
investigated. This study demonstrated that using AACID CEST MRI, a change in tumor
pHi can be detected after a glucose infusion is introduced. Tracking changes in tumor pH
could provide important information regarding the treatment response from chemotherapy
and/or radiotherapy. Hyperglycemia induced by a glucose infusion leads to a change in
tumoral pHi that can be detected in vivo using CEST MRI. The relationship between tumor
and peritumor pHi environment and tumor glycolysis were explored. Tumor Lac:Pyr is
significantly inversely proportional to tumor and peritumoral pHi, it is also significantly
directly proportional to tumoral and peritumoral ΔpHi induced by a glucose infusion. The
associations emphasize the innate relationship between tumor glycolytic metabolism and
the tumor pH environment as well as the peritumor pH environment. A multimodal
imaging approach could provide a more complete picture of the process of tumor
progression and invasion by monitoring both tumor glycolysis and the change in the pH
environment.
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There were several limitations from this study. To follow the radiation safety protocols at
different sites, the rats had to be housed at our PET facility overnight before they could be
transferred to the MR facility. In the future, experiments could be carried out on a hybrid
PET/MR system not only to simplify the experimental procedure but also to provide
simultaneous measurements under the same tumor pH and metabolic microenvironment.
The precise roles of glucose transporters were not examined in this study – histological
information about these transporters will be acquired in future studies, and the correlation
between the distribution of these glucose transporters and the tumor pHi environment can
then be evaluated [1,2]. A measurement of pHe would also aid in interpreting these results.
We plan on acquiring this information in a future study simultaneously with acidoCEST
[3,4] to provide a more complete picture of the tumor pH environment (see Chapter 4). The
current 60-min glucose infusion protocol leads to hyperglycemia by the end of the AACID
CEST experiment. The acute change in pHi environment after the glucose infusion was not
measured in the current study due to a different CEST acquisition protocol that was used
during the first half of glucose infusion. Moreover, the Lac:Pyr value obtained from the
MRSI right after would be elevated under hyperglycemia [5–7] – a CEST acquisition
promptly following a bolus injection of moderate dose will be implemented in the future
to avoid an overly large alteration of the tumor glycolytic environment.

5.3 Chapter 4:

Glucose Infusion Induced Change in Intracellular pH and Its
Relationship with Tumor Glycolysis in a C6 Rat Model of Glioblastoma.

In this chapter, both tumor intra- and extracellular pH environment was evaluated using
CEST MRI with AACID and acidoCEST techniques respectively. The change in tumor
pHi and pHe was measured after a glucose injection. The relationship between the tumor
pH environment and its glycolytic activity measured using dynamic FDG-PET was also
evaluated. This chapter demonstrated the possibility of measuring both intracellular and
extracellular pH simultaneously using CEST MRI. CEST MRI was also able to detect the
change in tumor pHi and pHe after a glucose injection. The intrinsic relationship between
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tumor and peritumor pH environments (tumor pHi and peritumor pHe) could potentially
help predict tumor invasion. Tumor glycolytic metabolism and its effect on tumor pHe was
also shown in this study. A strong correlation between tumor glycolysis and pHe might
suggest that acidoCEST measurement could be a surrogate measurement of tumor
glycolysis. The above findings illustrate the importance of understanding the tumor pH
environment as it relates to tumor metabolism.
Other than the limitations mentioned previously, there were a few limitations for the work
presented in this chapter: similar to what was mentioned previously, all imaging was done
in a sequential order, as a result the tumor glycolytic and pH environment were not identical
during the experiment. A simultaneous PET/MR system can potentially capture both tumor
glycolytic metabolism and its pH environment simultaneously in a single session. The
information regarding tumor hypoxia was missing from the presented study. Tumor
hypoxia will aggravate the acidosis in tumor pHe due to the Warburg effect [2,8,9]. Tumor
hypoxia can be investigated ex vivo using histopathology with pimonidazole [10,11], or in
vivo with hypoxia associated PET tracers such as 18F-flurozaomycin arabinoside (FAZA)
[12,13]. The kinetic analysis performed in this study assumed there is no reversible transfer
from the bound compartment to the free compartment using Patlak graphical analysis
[14,15]. A recent study demonstrated that the “trapped” 18F-FDG6P can be transferred back
to extracellular space [16]. A more sophisticated modeling method could be employed in
the future to account for the possible reversible pharmacokinetics of FDG.

5.4 Future Directions
All imaging presented in Chapter 2, 3 and 4 was done in a sequential order, and on multiple
scanners in 2 days, as a result, the tumor microenvironment was not identical. Future
experiments can be done using a PET/MRI system [17,18] to simplify the experimental
design and capture a more accurate snapshot of the tumor microenvironment.

116

This thesis investigated the relationship between tumor perfusion, glycolytic metabolism
and its pH environment, however the role that cancer hypoxia played in this vicious cycle
was not examined. Tumor hypoxia in combination with the Warburg effect will exacerbate
tumor acidosis [2,8,9,19]. The effect of hypoxia can be investigated invasively in vivo using
a probe measuring partial pressure of oxygen (pO2) [20], or using an implantable
microfabricated oxygen sensor [21]; it can be imaged non-invasively using PET with
hypoxia sensitive tracers such as 18F-flurozaomycin arabinoside (FAZA) [12,13] and 18Ffluronisonidazoles (FMISO) [22], or using optical sensing approaching with luminescent
probes described as Föster resonance energy transfer (FRET) complexes [23]; or via
histopathology using pimonidazole [24]. Future studies can incorporate some of the
techniques mentioned above to fill in the missing piece that tumor hypoxia plays in the
vicious cycle of tumor proliferation.
FDG-PET can provide information on tumor glycolytic activity [9], however, FDG can
also be taken up by cells such as microglia and tumor-associated macrophages activated
during an inflammatory response induced by cancer cells [25]. This could lead to
overestimation of tumor volume and tumor glycolytic metabolism using FDG-PET [26].
Ideally, the information related to inflammatory response could be measured separately
and also subtracted from FDG-PET so that tumor glycolysis can be estimated more
accurately. Multiple PET tracers have been developed to investigate inflammatory
response, including tracers such as
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C-PK11195 and

18

F-FEPPA that target the

translocator protein (TSPO) overexpressed in the mitochondria of activated microglia and
macrophages under inflammation [27,28]. However, these tracers will also target reactive
astrocytes, endothelial cells and glioma cells as well [29,30], resulting in an inaccurate
measurement of inflammation in a glioma model. A PET tracer targeting the macrophage
colony-stimulation factor 1 receptor (CSF1R) that is primarily expressed on microglia has
been developed [31]. Using a PET tracer targeting CSF1R might provide a more accurate
measurement of inflammation relative to TSPO tracers mentioned above [32]. Moreover,
these tracers can be labeled with a 20-minute half-life radioisotope 11C, such as 11C-CPPC,
and enable the possibility of imaging inflammation with 11C-CPPC and tumor glycolysis
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using 18F-FDG sequentially in one PET imaging session. CEST MRI can also be used to
evaluate inflammatory response by indirectly measuring the elevated endogenous
glutamate (~3 ppm downfield from bulk of water) during inflammation [33–35]. Future
experiments could perform a dual-tracer PET session sequentially using 11C-CPPC and 18FFDG to measure and separate inflammatory cells in the tumor from tumor glycolysis, a
CEST session measuring glutamate and/or pH can occur simultaneously using a PET/MR
system or an MR-compatible PET insert.
The simultaneous detection of intra- and extracellular pH with CEST can be utilized in
tracking cancer treatment response. As mentioned previously, cancer has a neutral to
slightly alkaline pHi and more acidic pHe [2,36], chemotherapy and/or radiotherapy would
reverse this pH distribution across the intracellular and extracellular space i.e., a more
acidic tumor pHi and more neutral pHe [37–39] in order to achieve a good treatment
outcome [37,40]. As a result, treatment response and progress can be tracked if the change
in cancer pH environment (both pHi and pHe) can be monitored throughout the treatment
session. In the future, experiments will be designed to monitor the change in tumor pH
environment for subjects receiving either chemotherapy or radiotherapy with AACID and
acidoCEST MRI. The effect of tumor metabolism can be tracked with FDG-PET
simultaneously using either a PET/MR system or an MR-compatible PET insert. Kinetic
analysis of FDG-PET can also be modeled more accurately by including a reversible
transfer rate constant (k4) as mentioned above. The relationship between the tumor pH
environment and its glycolytic activity can be examined longitudinally throughout the
treatment period. The effectiveness of the treatments either using chemotherapy or
radiotherapy can be accessed based on the change in tumor pH environment and its
glycolytic metabolism.

5.5 Conclusion
This thesis explored the intrinsic relationships between cancer perfusion, glycolysis and its
pH environment using a multimodal in vivo imaging approach. In Chapter 2, we show that
glucoCEST is more related to measurements of perfusion than glycolysis. In Chapters 3
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and 4, we show that the change in tumor pH environment can be monitored using CEST
MRI after a glucose injection. To our knowledge, this thesis includes the first study
measuring pHi and pHe simultaneously using CEST MRI in a single session (Chapter 4).
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